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Cancer is one of the leading causes of death in the western World and its incidence is 
continiously rising. Cancer is treated with chemotherapy, surgery, radiotherapy or targeted 
and immunotherapeutic anticancer drugs. Given the still disappointing cure rates there is 
ongoing research to improve efficacy of treatment and reduce treatment time and side 
effects. Chemotherapeutic drugs have proven efficacy in several tumor types. They damage 
tumor DNA and subsequently apoptosis of the tumor cell. Chemotherapy affects also 
normal cells which causes side effects, dose limiting toxicities and therefore a longer 
treatment time. In most tumor types combination chemotherapy is the most effective 
strategy. Chemotherapy regimens differ in side effects and therefore much research is done 
to find the most effective treatment with the fewest side effects. 
Another strategy is to try to select patients upfront or early during the course of the 
disease based on tumor characteristics for optimal treatment. In the last decades, tumor 
biological research has identified new molecular pathways involved in oncogenesis. This 
has resulted in the development of targeted anticancer therapies. Currently early tumor 
response measurements in drug development studies is based on the Response Evaluation 
Criteria for Solid Tumors (RECIST)1. This response measurement was developed with the 
help of a large ware house found and correlates with overall survival and is as such an early 
response predictor of drug effect2. Response evaluation according to RECIST is in general 
done after 2-3 cycles of systemic therapy3. However, prediction of response before initiation 
of therapy or earlier during treatment would clearly benefit the patient; patients who will 
not respond to a certain therapy do not have to suffer from the side-effects and can move 
on to a better therapy sooner. Molecular characteristics at initiation of treatment and early 
changes could potentially serve as predictive biomarkers and support treatment decisions 
at an early stage. Thus, potentially drug development and selection of the right patient for 
the right treatment could be optimized. 
In general for molecular characterization of tumors, a biopsy is required. Unfortunately, 
biopsies are not always feasible. Furthermore, it provides only static information on the 
status of a marker in a small part of the tumor and disregards the heterogeneity within 
remaining tumor tissue and metastases. Characteristics at the tumor cell membrane and in 
the microenvironment can be targeted with monoclonal antibodies. These are highly 
specific proteins, which bind to either a ligand or receptor of the (cancer) cell. Molecular 
imaging with radio-labeled monoclonal antibodies can potentially provide non-invasive 
whole body information about tumor uptake- and organ distribution of the monoclonal 
antibodies, and about the presence of the target in all lesions across the patient’s body. 
Molecular imaging with for example positron emission tomography (PET) can be easily 
serially performed by developing a tracer against a membrane receptor or a ligand. 
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An example of an important growth factor receptor in breast cancer is the human epidermal 
receptor (HER)2. Phosphorylation of HER2 leads to cell growth and differentiation. In 20-
25% of the breast cancer patients the HER2 gene is amplified and the protein overexpressed. 
Targeting this receptor with for example trastuzumab gives a survival benefit in the adjuvant 
as well as in the metastatic setting4,5. It is possible to visualize HER2 with radiolabeled 
trastuzumab6,7. Vascular endothelial growth factor (VEGF)-A is a key factor in angiogenesis 
and is broadly expressed in different types of cancer. It is the ligand of VEGF-receptors on 
the endothelial cells. Visualization of VEGF-A is possible e.g. with radiolabeled bevacizumab, 
which binds to all VEGF-A splice variants. 
Next to individual targets for cancer therapy, there is an interest for targeting multiple 
oncogenic factors at once. Heat shock protein (HSP) 90 is a molecular chaperone which is 
involvement in all hallmarks of oncogenesis, including HER2 and VEGF-A. HSP90 
inhibitors are currently tested in the clinic. 
This thesis aims at evaluating the potential clinical applications of an optimal 
chemotherapeutic regimen in patients with gestational trophoblastic neoplasia in order to 
improve treatment as well as radio-labeled monoclonal antibody imaging of HER2 and 
VEGF-A in breast cancer patients, for detection of targets in tumor lesions as well as 




Outline of the thesis
Primary therapy of high-risk gestational trophoblastic neoplasia consists of 
polychemotherapy. Etoposide (100 mg/m2 days 1-5) and cisplatin (20 mg/m2 days 1-5) 
(EP) could be a good alternative treatment regimen to etoposide 100 mg/m2 days 1-5, 
methotrexate 300 mg/m2 day 1, cyclophosphamide 600 mg/m2 day 1, actinomycin D 0.5 
mg/m2 day 2 and cisplatin 50 mg/m2 day 4 (EMACP), aiming for comparable effectiveness 
with a shorter total treatment time. 
In chapter 2 we evaluate the efficacy, treatment time and safety of EP as compared to 
EMACP. All patients with high risk GTN who were treated with EP in our institution 
between 2001 and 2013 were included in this retrospectively analysis and compared with 
the results of patients treated with EMACP between 1984 and 2001. Disease specific 
survival, duration of therapy and major toxicity were reported. 
In chapter 3, the roles of current and future potentials of molecular imaging in drug 
development are reviewed with imaging of HER2 and VEGF-A as role models. We describe 
in more detail the information that has been obtained with trastuzumab and bevacizumab 
immuno positron emission tomography (PET) and single photon emission computed 
tomography (SPECT) imaging. This information could support the use of immunoPET 
imaging in the development of other antibodies and targeted anticancer agents.
Breast cancer prognosis and response to treatment appear to be partly dependent on 
microenvironmental characteristics9. Therefore, targeting factors in the tumor 
microenvironment that support the process of tumor progression and development of 
metastases, may be a rational way to improve therapies to treat cancer patients. In chapter 
4, we review the targets in the microenvironment that can potentially be modulated to 
improve patient outcome. Articles for this review were found by searches of PubMed, 
abstracts American Association for Cancer Research (AACR) and American Society of 
Clinical Oncology (ASCO) and the clinicaltrials.gov database by use of the terms 
‘microenvironment’ combined with ‘metastasis’ ‘metabolic dysfunction’ ‘migration’ ‘immune 
cells’ ‘angiogenesis’ or ‘matrix remodeling’ and combinations of these terms with the 
selected soluble factors. In addition, relevant papers from the reference lists of selected 
papers were included. Only studies written in English were included. 
Loss or gain of HER2 expression can have clear therapeutic consequences, as patients 
with HER2 positive lesions benefit from anti-HER2 therapy9,10. This underlines the necessity 
to accurately assess HER2 status during the course of metastatic breast cancer. Non-invasive 
determination of HER2 expression can be performed with molecular imaging. In the 
clinical setting HER2 imaging is performed with trastuzumab radiolabeled with 111In and 
with the positron emitting tomography (PET) isotope zirconium-89 (89Zr)6,7. One of the 
hurdles in implementation HER2 imaging in clinical practice is the unknown effect of 
trastuzumab on in vivo molecular HER2 imaging. We previously reported on 111In-
trastuzumab scintigraphy in 17 patients with HER2 overexpressing metastatic breast cancer 
after the first loading dose of trastuzumab6. Part of these patients underwent a second 
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scintigraphy after treatment. Therefore the aim of the study described in chapter 5 is to use 
the serial scintigraphy data to assess the effect of trastuzumab treatment on tumour uptake, 
biodistribution and radiation dosimetry of 111In-trastuzumab. 111In-scintigraphy was 
performed before and during treatment with paclitaxel and trastuzumab. Patients received 
6 once-every-3-weeks cycles trastuzumab (2 mg/kg) and paclitaxel (175 mg/m2) every 
3 weeks. 111In-trastuzumab was injected on day 1 of the first cycle and day 15 of the fourth 
cycle. Whole-body planar scintigraphy scans were acquired on 4 different time points from 
15 minutes until 7 days postinjection. Differences in tumor and organ uptake were 
determined from radiation dosimetric data and expressed as residence time (defined as area 
under the curve of radioactivity versus time). Radiation dose of tumors and organs and 
effective dose were calculated.
Chapter 5B describes the clinical value of the 89Zr-trastuzumab PET in a patient with 
a diagnostic dilemma. 
In chapter 6, the clinical feasibility of VEGF-A imaging with 89Zr-bevacizumab in patients 
with primary breast cancer is presented. Prior to surgery, breast cancer patients underwent a 
PET/CT scan of breasts and axillary regions, 4 days after injection of the tracer 89Zr-bevacizumab 
administration intravenously. 89Zr-bevacizumab uptake was quantified as the maximum standard 
uptake value (SUVmax). Quantification of 
89Zr-bevacizumab levels in primary tumor lesions, 
metastatic lymph nodes as well as physiologic uptake in breast and bloodpool is performed. PET 
images were compared with standard imaging modalities. VEGF-A levels in tumor and normal 
breast tissues were assessed with Enzyme-Linked Immuno Sorbent Assay (ELISA) and 
immunohistochemistry and compared with the PET results.
 HSP90 chaperones protect key client proteins involved in all hallmarks of breast cancer 
growth and progression including HER2 and hypoxia inducible transcription factor (HIF)-
1α11. The latter results in downregulation of VEGF-A. Therefore HER2 and VEGF-A 
downregulation are potential early predictive biomarkers for the response to drug that act 
as HSP90 inhibitors. Previously, HER2 and VEGF-A imaging following HSP90 inhibition 
was performed in mice bearing a human xenograft model12,13. In chapter 7, the study is 
presented in which patients with metastatic or locally advanced breast cancer (HER2 or ER 
positive) were treated with the HSP90 inhibitor NVP-AUY922. 70mg/m2 NVP-AUY922 
was administered intravenously on a weekly schedule in the University Medical Center 
Groningen or The Royal Marsden Hospital London. Here, we searched for a biomarker to 
predict tumor response. 18F-fluordeoxyglucose (FDG)-PET and CT were performed pre-
treatment and at different time points during treatment. In addition, patients underwent an 
89Zr-bevacizumab PET (in estrogen receptor (ER) positive patients) or 89Zr-trastuzumab 
PET (in HER2 positive patients) pre-treatment and after 3 weeks. In blood samples, serial 
HSP70 levels and extracellular form of HER2 (HER2-ECD) were measured. Quantification 
of 89Zr-bevacizumab-and trastuzumab levels in all lesions as well as physiologic uptake in 
organs was performed. PET data were compared with conventional imaging.
In chapter 8 and 9, the findings of this thesis are summarized, followed by a general 
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Background: Therapy of low risk gestational trophoblastic neoplasia (GTN) not responding 
to monotherapy and primary high risk GTN consists of polychemotherapy. EMACP, a 
regimen consisting of etoposide (100 mg/m2 d1-5), methotrexate (300 mg/m2 d1), 
cyclophosphamide (600 mg/m2 d1), dactinomycin (0.5 mg/m2 d2) and cisplatin (50 mg/m2 
d4) intravenously, is effective. Etoposide (100 mg/m2 d1-5) and cisplatin (20 mg/m2 d1-5 
intravenously; EP) may be an alternative regimen with comparable efficacy and a shorter 
treatment time. After normalization of the βhCG serum levels, patients treated with EMACP 
received 2 additional consolidation cycles, which is not the case for EP. In this study we 
evaluate the safety, efficacy, and treatment time of EP.
Methods: All patients with high risk GTN who were treated since 2001 with EP at our 
institution were included in this retrospectively cohort analysis and compared with the 
results of patients treated between 1984-2001 with EMACP. Disease specific survival, 
duration of therapy and major toxicity are reported. 
Results: Thirteen and 16 patients started treatment with respectively EP and EMACP. With 
a median follow up duration of 173 months (range 11-344) overall survival rates are 
comparable for both regimens (EP 92.3%, EMACP 93.8%; P = 0.88). Median treatment 
time was shorter with EP (EP 78, range 63-84 days; EMACP 110, range 84-168 days; 
(P = 0.006). Respectively 3 and 9 patients were hospitalized for pancytopenia (P = 0.17). 
One patient developed an allergic reaction on EMACP. Three patients on EP experienced a 
thromboembolic event and one patient was hospitalized for diarrhea. 
Conclusion: In this retrospective single institution analysis of the treatment of high risk 
GTN the EP regimen has survival rates in the same range as EMACP with comparable 




Gestational trophoblastic disease (GTD) defines a spectrum of tumors originating from the 
placenta. The resulting proliferative process has the potential to develop into the malignant 
subset of gestational trophoblastic neoplasia (GTN). The spectrum of GTN is characterized 
by their aggressive invasion into the myometrum and propensity to metastasize. 
Histologically, these tumors include invasive mole, choriocarcinoma, placental site 
trophoblastic tumor and epithelioid trophoblastic tumor. The most common malignant 
form of GTN is choriocarcinoma, which arises from an antecedent pregnancy, either a 
molar or normal conceptus. GTN is one of the most chemotherapy-responsive and highly 
curable cancers, even in the setting of widespread metastatic disease1.
Low risk GTN, which is defined as a WHO prognostic score of 0-62, is treated with 
methotrexate or dactinomycin. When this fails, or in case of high risk GTN, which is 
defined as a WHO prognostic score of ≥7, several combination chemotherapy regimens 
have been advocated3. However, the necessity for polychemotherapy is not frequent due to 
the low incidence of GTN and the effective treatment of low risk GTN with monotherapy. 
A combination of etoposide, methotrexate, dactinomycin, cyclophosphamide and 
vincristine (EMA-CO) is the most used polychemotherapy regimen in high-risk GTN with 
a 80% complete remission rate4. The EMA-CO regimen was retrospectively compared with 
methotrexate plus folate acid and dactinomicin (MTX+Act-D), methotrexate, dactinomycin 
and cyclophosphamide or chlorambucil (MAC) and cyclophosphamide, hydroxurea, 
dactinomycin, methotrexate with folate acid, vincristine and doxorubicin (CHAMOCA). 
The EMA-CO regimen had the highest complete remission rate with few toxic effects5. 
However, a significant part of patients treated with EMA-CO did require salvage 
chemotherapy with a platinum containing regimen1. Especially in case of liver and/or brain 
metastases 5-year survival is poor, 35.3% and 70.6% respectively6. The 5-year survival of 
the subgroup of patients with both liver and brain metastases is only 10%7. In a recent 
study, etoposide and cisplatin (EP) followed by etoposide, methotrexate, and dactinomycin 
weekly alternated with cyclophosphamide and vincristine (EMA-CO) nearly completely 
prevented early deaths in that phase II study8. Besides induction therapy, platinum-based 
chemotherapy can also be the primary curative regimen. Remission rates in platinum-
based chemotherapy, consisting of etoposide, methotrexate, cyclophosphamide, 
actinomycin D and cisplatin (EMACP), are in the same range as that of EMA-CO9. However, 
both these regimens need two consolidation cycles after normalization of the β-human 
chorionic gonadotropin (βhCG). 
As GTN histologically mimics testicular germ cell tumours, which can be cured with 
etoposide and cisplatin10, this compact regimen can also be used as a first line treatment in 
GTN without the need of consolidation cycles. Here, we report the results of the EP regimen 
in patients with high-risk GTN treated at our institution from 2001. These results were 
compared with the results of the EMACP regimen in a comparable patient population 
treated until 2001. 
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Data from patients who were treated at our institution with EP or EMACP for primary 
high-risk GTN or after failure of previous chemotherapy for low-risk GTN were collected 
retrospectively. EMACP was standard of treatment from 1984 till 2001, thereafter EP 
became our first-line polychemotherapy regimen. Patients were classified using the 
modified WHO prognostic scoring system. Patients with WHO scores of 0 to 6 were 
considered to have low-risk disease, whereas those with a score of 7 or higher were 
considered high-risk.
Treatment
EP was administrated intravenously during five subsequent days in a three-weekly interval: 
etoposide 100 mg/m2/day and cisplatin 20 mg/m2/day. In this protocol, 3 cycles of EP were 
administered if the βhCG was normalized at the start of the second cycle; in all other cases 
the patients received four cycles of EP. Normalization of βhCG was defined as a serum 
βhCG level below 5 IU/L. This protocol was analogous to the testicular germ cell tumor 
treatment protocol, except that bleomycin was not given to GTN-patients. In the EMACP 
regimen, etoposide 100 mg/m2 days 1-5, methotrexate 300 mg/m2 day 1, cyclophosphamide 
600 mg/m2 day 1, dactinomycin 0.6 mg/m2 day 2 and cisplatin 60 mg/m2 day 4 were 
administered intravenously in a four-weekly interval. After normalization of the βhCG 
serum levels, patients treated with EMACP received 2 additional consolidation cycles. In 
both regimens, surgical resection of the most suspicious residual tumor focus was 
considered if the βhCG did not normalize.
Outcomes
βhCG levels were measured at the start of each cycle and once between two cycles of 
chemotherapy. Before the year 2000, the immunoradiometric assay from Amersham 
Buchler, Braunschweig, FRG was used. In 2000 this assay was changed to Architect from 
Abbot, IL. All values were converted to IU/L. The time to normalization was defined as the 
time from the first treatment day until the first βhCG value below 5 IU/l. Outcome measures 
were the overall survival, the mean number of chemotherapy cycles required to achieve 
complete remission (defined as βhCG value below 5 IU/l) and the duration of therapy. 
Toxicity was registered using the Common Terminology Criteria for Adverse Events 





Data are presented as median ± standard deviation (SD). Patient characteristics, remission 
rates and toxicity were compared using Fisher’s exact or Chi-square test. Mean age, time to 
normalization, time of treatment and mean number of chemotherapy cycles were compared 
using Student t-test or Mann-Whitney U test. A double sided P-value <0.05 was considered 
significant. 
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A total of 29 patients with high-risk GTN, or with low-risk disease that failed on prior 
chemotherapy, have been treated with EP (n=13) or EMACP (n=16) between 1984 and 
2013 at our institution. Patient characteristics are summarized in Table 1. 
Table 1. Patient characteristics at start of the polychemotherapeutic treatment
EP (N=13) EMACP (N=16) P-value
Age at diagnosis (years)
  Mean ± SD 31 ± 4.6 31 ± 6.9 0.82
Antecedent pregnancy
  Hydatidiform mole 
  Term pregnancy 











WHO score at primary diagnosis
  Median (range) 8 (2-20) 13 (3-15) 0.53
βhCG at start of polychemotherapy
  Median (range) 1.1*104 (21-1.2*106) 1.7*104 (4-1.5*105) 0.08
Indication of chemotherapy
  Single-agent resistant disease






In the EP group, one patient died due to an intracranial bleeding in a brain metastasis 
after the first EP cycle. The remaining 12 patients achieved complete remission. In the 
EMACP regimen, 15 of the 16 patients achieved complete remission. One patient died due 
to sepsis after the first cycle of EMACP. During follow up, no patients developed recurrent 
disease (median follow-up EP-regimen 93 months, range 11-150; median follow-up 
EMACP-regimen 280 months, range 170-344). Disease specific survival of EP patients was 
92.3% and 93.8% for patients initially treated with EMACP (P = 0.88). Median time to 
βhCG normalization was 50 days, range 13-177 for the EP regimen compared to a median 
of 32 days, range 3-72 for EMACP (P = 0.17). 
Median treatment time was 78 days  (range 63-84) for patients treated with EP 
compared to 110 days (range 84-168) for patients treated in the EMACP regimen 
(P = 0.006). 
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In both treatment regimens one patient died during treatment. A total of 9 patients who 
received EMACP (56.3%) and 3 who received EP (30.8%) were hospitalized for 
pancytopenia with neutropenic fever (P = 0.17). One patient treated with EMACP developed 
an allergic reaction, probably due to cisplatin, for which she was successfully treated in the 
intensive care unit. Three patients treated with EP had a thrombotic event during treatment 
and one patient was hospitalized for diarrhea grade 4, which subsided within 5 days with 
supportive treatment (Table 2).
Table 2. Toxicity requiring hospitalization

















To the best of our knowledge, this is the first paper reporting on the results of EP as first 
line polychemotherapy for high-risk GTN or low risk GTN unresponsive to monotherapy. 
The present analysis shows that disease specific survival rates of patients treated with EP 
were in the same range as that of patients treated with EMACP with a shorter total treatment 
time. Patients treated with EP appeared to have more often thrombotic events and diarrhea. 
However patients treated with EMACP were hospitalized more frequently for neutropenic 
fever and thrombocytopenia. This study was too small to study long-term side effects. The 
relatively high risk of secondary malignancies after polychemotherapy for GTN found in 
other studies is expected to be related to the cumulative dose of etoposide9. Long-term 
effects of EP are quite extensively studied in patients with testicular cancer11, in contrast to 
the long-term effects of EMACP. A total of 82 patients received a cumulative dose of at least 
2 g/m2 of etoposide, after which 5 (6.1%) developed leukaemia within 10 years after 
treatment12. Whereas no patients developed leukaemia in a study in which patients received 
less than 2 g/m2,13. Each cycle of EP and EMACP contains the same amount (500 mg/m2) of 
etoposide. The EMACP regimen required slightly more cycles compared to EP, and thus 
higher cumulative dose of etoposide, which may have the consequence of a higher risk for 
secondary leukaemia in EMACP. The higher prevalence of bone marrow toxicity in EMACP 
compared to EP may be a sign of this increased risk. Although EMACP might encompass a 
higher risk for secondary malignancies compared to EP, the EP regimen has serious vascular 
side effects. In the EP regimen, the total cisplatin dose (100 mg/m2 per cycle) is higher 
compared to the EMACP regimen (60 mg/m2). Cisplatin is associated with thrombotic 
events during treatment14. The long-term effects of cisplatin involve mainly neurotoxicity, 
renal and vascular toxicity15, which might be more prominent in patients treated with EP. 
The time to βhCG normalization did not differ significantly between the two treatment 
regimens. However, most patients treated with EMACP were treated before the year 2000, 
whereas patients treated thereafter mainly received EP. Moreover, more patients treated 
with EMACP had single-agent resistant disease. At earlier times, less extensive pre-treatment 
imaging was performed. That way, sites of metastases might be missed which leads to lower 
WHO scores. The change in the βhCG assay diminishes the uniformity of the assay, but 
will not influence the time to normalization. 
In this study we have shown that EP combination chemotherapy is a feasible treatment 
for high-risk GTN. The confidence interval of the remission rates and long-term survival of 
EP are overlapping with EMACP, while the treatment time was shorter with EP. There were 
no relevant different toxicity profiles for EP and EMACP. It seems feasible to decrease the 
intensity of the treatment of high-risk GTN and put 3 or 4 cycles of EP as initial treatment. 
A randomized control trial is needed to confirm the results of this retrospective study 
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Abstract 
ImmunoPET is the noninvasive imaging of specific targets with radiolabeled monoclonal 
antibodies. These tracers can give information about tumor uptake and about presence of 
the target in all tumor lesions across the patient’s body. ImmunoPET can be used to evaluate 
changes in target as consequence of treatment with monoclonal antibody and non-
monoclonal antibody targeted drugs. It can also potentially contribute to optimal patient 
selection for targeted therapy. In this chapter, we illustrate these potential applications of 
immunoPET by means of preclinical and clinical imaging studies performed with the 
radiolabeled monoclonal antibodies trastuzumab and bevacizumab for visualization of the 




In the last decades, many new targets for anticancer drugs have been identified and this has 
led to the development of the targeted anticancer therapies. Among them are monoclonal 
antibodies. Monoclonal antibodies are highly specific proteins, which bind to either a 
ligand or receptor of the (cancer) cell and several monoclonal antibodies have been 
approved over the last years for use as therapeutic drug in oncology. Currently there are 
limited options to predict who is going to respond to these targeted therapies. Even with 
the progress that has been made in the selection of a high HER2 expression in tumors of 
patients treated with the monoclonal antibody trastuzumab or selection of wild-type KRAS 
in patients treated with cetuximab or panitumumab, there is still a need to improve the 
selection of patients so as to receive the most optimal treatment.
Noninvasive imaging of specific targets with radiolabeled monoclonal antibodies can 
give information about tumor uptake and organ distribution of the monoclonal antibodies 
and about the presence of the target in all lesions across the patient’s body. Monoclonal 
antibodies can be radiolabeled with varying radio-isotopes and can, depending on the 
isotope, be imaged by single photon emission computed tomography (SPECT) or positron 
emission tomography (PET). The physical half-life of the radio-isotope should suit the 
kinetics of tumor accumulation and non-tumor clearance of the monoclonal antibodies to 
allow imaging at the time-point of optimal tumor accumulation. Monoclonal antibodies 
have a long serum half-life of, often more than ten days. They are predominantly excreted 
through hepatic clearance, due to their large molecular weight around 150 kDa, which is 
above the kidney threshold of approximately 50 kDa. Large monoclonal antibodies 
penetrate slowly but constantly into solid tumor tissue. Because the serum clearance is low, 
the slow penetration results over days in an increasing tumor accumulation. For adequate 
visualization with slowly accumulating monoclonal antibodies the isotopes should also 
have long half-lives, like Indium-111 (111In; t 1/2 67h) for SPECT and Zirconium-89 (
89Zr; t 1/2 
78h) for PET imaging. In order to minimize bone marrow, thyroid, liver or kidney toxicity, 
the half-life of the isotope should not exceed the biological half-life of the monoclonal 
antibodies. PET potentially provides a higher spatial resolution, a better signal-to-noise 
ratio and allows a superior quantification compared to SPECT.
Over the last years we performed pre-clinical as well as clinical imaging studies with 
radiolabeled trastuzumab, which binds to HER2 and with radiolabeled bevacizumab which 
binds to all vascular endothelial growth factor (VEGF)-A splice variants.
In this chapter we describe in more detail the information that has been obtained with 
trastuzumab and bevacizumab immunoPET imaging. This information could support the 
use of immunoPET imaging in the development of other antibodies and targeted anticancer 
agents.
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HER2 visualization 
HER2 is a member of the ErbB tyrosine kinase receptor family and consists of an extracellular 
domain, a transmembrane segment and an intracellular protein kinase domain. HER2 is 
involved in cellular growth, survival, proliferation and maturation in metastases and 
angiogenesis, and has anti-apoptotic effects. Over-expression of this receptor due to gene 
amplification occurs in 20-30% of all breast cancers and in a lower percentage in gastric 
and esophageal cancers1. Trastuzumab is a humanized monoclonal antibody targeting the 
extracellular domain of HER2 and is used in the treatment of patients with HER2 over-
expressing breast cancer. The addition of trastuzumab to chemotherapy has increased 
tumor response rate and survival in the metastatic setting, and disease free- and overall 
survival in the adjuvant setting. HER2 tumor expression can vary during treatment in an 
individual patient and can differ between metastatic lesions within a patient. In the 
metastatic setting almost all patients will develop resistance for this drug. 
To allow in vivo HER2 imaging, we developed 111In-trastuzumab. Tumor uptake and 
biodistribution of 111In-trastuzumab was studied in HER2-positive and –negative human 
tumor-bearing mice. The HER2 positive tumor showed substantially more uptake of 111In-
trastuzumab compared to the HER2 negative tumor. The difference in 111In-trastuzumab 
uptake between HER2-positive versus negative tumors was already measurable five hours 
after injection and was even more pronounced three days after injection. Liver spleen and 
kidney showed marked non-specific uptake, which is normal for 111In-labeled antibodies2. 
111In-trastuzumab was clinically used in HER2 positive metastatic breast cancer 
patients. With SPECT imaging we were able to visualize new lesions, previously unidentified 
with standard staging techniques, in 13 out of 15 patients3. 
A side effect of trastuzumab is cardiotoxicity, which occurs particularly when 
trastuzumab is combined with anthracyclines. HER2 in the heart plays a key role during 
embryogenesis. Myocardial HER2 expression may be transiently upregulated by a 
compensatory mechanism following cardiac stress. In a clinical trial, we evaluated whether 
myocardial HER2 expression (as measured by 111In-trastuzumab SPECT) is upregulated by 
anthracycline-induced cardiac stress or in case of heart failure by chronic pressure or 
volume overload. To this end, 111In-trastuzumab scans were performed in breast cancer 
patients shortly after anthracyclines as well as in patients with non-anthracycline-related 
heart failure. Shortly after completion of anthracycline treatment, myocardial HER2 
overexpression was detectable in 50% of the patients, while none of the non-anthracycline-
related heart failure patients showed myocardial uptake4.
After these 111In-trastuzumab SPECT studies, the long-lived PET-isotope 89Zr became 
available for clinical immunoPET imaging with 89Zr-labeled antibodies. For labeling of 
internalizing monoclonal antibodies positron emitting radiometals like 89Zr are preferable 
over radiohalogens like 124I. This is because positron emitting radiometals are retained 
within the target cell after internalization and intracellular degradation of the tracer. Of the 
available positron emitting radiometals, 89Zr has the most favorable half-life of 78.4 hours, 
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allowing antibody imaging up to seven days postinjection. Pre-clinical evaluation of 89Zr-
trastuzumab displayed equal tumor uptake for 89Zr-trastuzumab compared to 111In-
trastuzumab, but the superior image quality of 89Zr-trastuzumab is due to the high spatial 
resolution and sensitivity of PET, while there was an equal tumor uptake for 89Zr-
trastuzumab and 111In-trastuzumab. In addition, PET-imaging has the advantage of data 
quantification and whole body 3D imaging5.
To investigate the use of 89Zr-trastuzumab for HER2 PET imaging, a clinical feasibility 
study was performed to determine required conditions of 89Zr-trastuzumab antibody dose 
and timing. HER2-positive metastatic breast cancer patients received 37 MBq 89Zr-
trastuzumab at three trastuzumab protein doses (10 or 50 mg when trastuzumab naïve and 
10 mg while on trastuzumab treatment) and underwent ≥ 2 PET-scans around days 2 and 
5 post tracer injection. The best moment to assess 89Zr-trastuzumab tumor uptake was 4-5 
days postinjection. Trastuzumab naive patients required 50 mg 89Zr-trastuzumab and 
patients on trastuzumab treatment 10 mg. Accumulation of 89Zr-trastuzumab allowed PET 
imaging of known tumor lesions in the liver, lung, bone and brain as well as unknown 
brain and bone metastases. In conclusion 89Zr-trastuzumab PET at appropriate antibody 
dose allows visualization and quantification of uptake in HER2 positive lesions in metastatic 
breast cancer patients6.
The current practice of trastuzumab dosing for metastatic breast cancer is based on 
patient body weight. However, there are clues that trastuzumab pharmacokinetics and 
organ distribution can be affected by extensive tumor load. We showed in a patient with 
extensive HER2 positive liver metastases that 89Zr-trastuzumab was predominantly taken 
up by these liver metastases and rapidly cleared from the circulation. The rapid 89Zr-
trastuzumab clearance in this patient can theoretically be explained by rapid binding of 
trastuzumab molecules to the many HER2 receptors in the large liver metastases. The 
HER2 PET scan was repeated after start with trastuzumab in a therapeutic dose. Compared 
to the first HER2 PET scan, this scan showed less 89Zr-trastuzumab liver uptake, a higher 
blood pool level and more uptake in other tumor lesions such as bone metastases7. This 
indicates that only after saturation of the HER2 receptors in the liver metastases are other 
lesions reached by trastuzumab. This implies that for adequate dosing of trastuzumab, 
tumor load should presumably be taken into account.
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VEGF visualization
Vascular endothelial growth factor (VEGF), released by tumor cells, is an important factor 
in angiogenesis. Angiogenesis, the formation of new blood vessels, is important for the 
growth of tumors. In tumor cells there is an unproportional up-regulation of VEGF 
production which leads to locally high VEGF levels. The humanized monoclonal antibody 
bevacizumab blocks VEGF-induced tumor angiogenesis by binding and thereby neutralizing 
VEGF-A.
To select patients who could benefit from VEGF targeted therapies imaging of VEGF 
using specific tracers, is of great interest.
We developed 111In- and 89Zr-bevacizumab which showed specific tumor uptake in a 
human ovarian xenograft model. MicroPET imaging using 89Zr-bevacizumab showed clear 
tumor localization 72 hours post-injection with maximal uptake 168 hours post-injection, 
which was similar to ex vivo biodistribution. 89Zr-bevacizumab tumor uptake could be 
quantified non-invasively, allowing follow-up of VEGF secretion during therapy8. Clinically, 
89Zr-bevacizumab is used in renal cell cancer patients. In these tumor lesions, there is a 
high tumor-to-background ratio9. In melanoma patients 111In-bevacizumab was used to 
compare 111In uptake before and after treatment with bevacizumab. A single dose of 
bevacizumab slightly decreased 111In-bevacizumab uptake10.
Imaging drug effects
ImmunoPET could also be used to follow in vivo pharmacodynamic effects of other targeted 
drugs. Heat Shock Protein 90 (HSP90) is a molecular chaperone that assists in the structural 
formation and folding of a wide variety of oncogenic client proteins including HER2 and 
HIF-1α (which drives VEGF excretion). Currently, there are several inhibitors of HSP90 in 
clinical development. In tumors, HSP90 exists in an activated state, with higher affinity for 
HSP90 inhibitors, compared with normal cells. HER2 down-regulation is a potential 
biomarker for early response to HSP90-targeted therapies, therefore we used 89Zr-
trastuzumab to quantify the alterations in HER2 tumor expression after NVP-AUY922 
treatment, a potent HSP90 inhibitor. The HER2 over-expressing human SKOV-3 ovarian 
tumor cell line was used for in vitro experiments and as xenograft model in nude athymic 
mice. For in vivo evaluation, mice received 50 mg/kg NVP-AUY922 intra-peritoneally every 
other day. 89Zr-trastuzumab was injected intravenously six days before NVP-AUY922 
treatment and after three NVP-AUY922 doses. MicroPET imaging was performed at 24, 72 
and 144 hours post-tracer injection followed by ex vivo biodistribution and 
immunohistochemical staining. PET tumor quantification showed a mean reduction of 
41% (P = 0.0001) in 89Zr-trastuzumab uptake, 144 hours post-tracer injection after NVP-
AUY922 treatment. PET results were confirmed by ex vivo 89Zr-trastuzumab biodistribution 
and HER2 immunohistochemical staining. Thus it was shown that down-regulation of 
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HER2, by means of HSP90 inhibition, can be non-invasively monitored and quantified 
with 89Zr-trastuzumab PET11,12. 
VEGF expression is regulated by HIF-1α, which is also a client protein of HSP90. 
Therefore, we investigated whether the effect of HSP90 inhibition could also be evaluated 
by means of visualizing VEGF downregulation in vivo. We performed 89Zr-bevacizumab 
micro-PET in a mouse model with A2780 human ovarian tumor, pre- and post-NVP-
AUY922 treatment. Ex vivo tumor VEGF levels and histological response were used as 
verification. Two weeks of NVP-AUY922 treatment decreased 89Zr-bevacizumab tumor 
uptake with 44% (P = 0.0003) compared to pre-treatment values. The same downregulation 
pattern was observed when tumor VEGF levels were measured with ELISA, and mean 
vessel density following NVP-AUY922 treatment12. This technique is currently under 
clinical evaluation in an ongoing clinical study to investigate whether 89Zr-labeled 
trastuzumab or bevacizumab visualization of HER2 and VEGF can serve as an early 
biomarker for HSP90 inhibition in HER2 positive metastatic breast cancer patients. 
Sunitinib is an anti-angiogenic compound which targets the VEGF receptor and has shown 
activity against various tumor types. Currently no biomarkers are available to select patients 
or function as early response predictor. Previously, we showed that radiolabeled 
ranibizumab, an anti-VEGF Fragment antibody (Fab) tracer with high affinity for all 
VEGF-A isoforms, allows non-invasive, frequent, quantitative and rapid insight in VEGF 
levels in the tumor and its microenvironment. Therefore, radiolabeled ranibizumab was 
used to monitor sunitinib treatment to obtain insight in locoregional changes in tracer 
uptake during therapy. Direct cytotoxicity of sunitinib was evaluated in vitro in a high 
VEGF producing human A2780 ovarian tumor cell line. Nude mice were inoculated with 
A2780 cells. When the tumor was established, mice were treated once daily with sunitinib 
(60 mg/kg intraperitoneally) or vehicle for seven days followed by a stop week, thus 
reflecting the patient regimen, or sunitinib/vehicle was continued for seven days. 89Zr-
ranibizumab (or control 89Zr-Fab-IgG for aspecific uptake) was injected at baseline, 
following seven or 14 days of treatment. MicroPET images were made 0, 6 and 24 hours 
post-injection of the tracer. 89Zr-ranibizumab revealed an inhomogeneous change in tumor 
uptake with a rebound phenomenon after stopping sunitinib treatment, resulting in 59% 
increased tracer uptake which corresponded with rapid tumor growth and an increase of 
plasma human VEGF levels. Clinically, VEGF PET is a good candidate to be explored for 
individual guidance of optimal anti-angiogenic therapy13.
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Conclusion
ImmunoPET can serve as a tool in drug development. We addressed results with this 
sensitive PET technique. The newly developed tracers can potentially play a role as 
biomarker in drug development. There are several tumor characteristics candidate for 
development of tumor specific tracers. Imaging drug targets, such as illustrated by several 
studies performed with radiolabeled trastuzumab and bevacizumab, can be used to evaluate 
the presence of the target in every lesion. Further studies should define whether these 
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It is increasingly evident that not only breast cancer cells, but also the tissue embedding 
these cells: the tumor microenvironment, plays an important role in tumor progression, 
metastasis formation and treatment sensitivity. This review focuses on the current 
knowledge of processes by which the microenvironment affects breast cancer, including 
formation of the metastatic niche, metabolic stimulation, stimulation of tumor cell 
migration, immune modulation, angiogenesis and matrix remodeling. The number of 
drugs targeting key factors in these processes is expanding, and the available clinical data 
is increasing. Therefore current strategies for intervention and prediction of treatment 
response are outlined. At present, targeting the formation of the metastatic niche and 
metabolic stimulation by the breast cancer microenvironment, are already showing clinical 
efficacy. Intervening in the stimulation of tumor cell migration and immune modulation by 
the microenvironment are upcoming fields of great research interest. In contrast, targeting 
microenvironmental angiogenesis or matrix remodeling appears to be of limited clinical 
relevance in breast cancer treatment so far. Further research is warranted to optimize 
intervention strategies and develop predictive tests for the relevance of targeting involved 





Breast cancer is the most common cause of cancer death among women worldwide1. In 
2010, 207,090 women were diagnosed with breast cancer in the United States2. 
Approximately 6% of all breast cancer patients have metastatic disease at the time of 
diagnosis, and currently 20% will eventually develop metastatic breast cancer (MBC)3. 
Once metastasized, breast cancer is generally incurable. 
Recent treatment strategies focus on induction of tumor cell death using 
chemotherapeutic, anti-hormonal and targeted agents. However, it is increasingly 
recognized that not only the tumor cells, but also the tissue embedding the tumor cells; 
their microenvironment, plays an important role in tumor progression and metastasis. This 
role in the complexity of metastasis4 can be assumed from the metastatic pattern of breast 
cancer to specific organs5. The importance of the cancer microenvironment is underlined 
by the recent inclusion of the microenvironment in the so called “hallmarks of cancer”6,7. 
Furthermore, microenvironmental characteristics affect breast cancer prognosis and 
chemosensitivity, and as such are increasingly incorporated in gene expression profiles8,9. 
Novel drugs targeting key factors in the microenvironment are being developed.
The tumor microenvironment includes soluble factors, extracellular matrix (ECM) and 
stromal cells10. Involved soluble factors comprise growth factors, hormones, immuno-
globulins, cytokines and chemokines10. The ECM contains proteoglycans, hyaluronic acid 
and fibrous proteins (collagen, fibronectin and laminin). Involved stromal cells include 
fibroblasts, (pre-)adipocytes, cells of the vascular system (endothelial cells) and immune 
cells11,12. Combinations of different cellular, extracellular and soluble factors can act to 
support multiple processes in the breast cancer microenvironment that promote progression 
and metastasis. This review focuses on the current knowledge of processes involved in the 
breast cancer microenvironment, and how they affect breast cancer progression and 
metastasis. These processes include: formation of the metastatic niche, metabolic 
stimulation, stimulation of tumor cell migration, immune modulation, angiogenesis and 
matrix remodeling. We will place them in order of importance as targets for breast cancer 
therapy, with the currently available (pre) clinical evidence (Table 1). Furthermore, we will 
outline present data with regard to strategies for monitoring treatment effect. Finally, we 
will describe potential future directions exploiting the microenvironment in breast cancer 
treatment.
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Table 1. Currently available (pre)clinical evidence for targeting microenvironmental processes
Process Factor Targeting Level of evidence* References Possible biomarker
Accommodation of 
distant metastases
TGFβ Anti-TGFβ1 antibodies (1D11, GC10081), 
TGFβR TKI (Ki26894, LY215799, 
LY2109761), bisphosphonates# (zoledronic 
acid 2-6)
4, 1 (21, 31) PSmad2 level 
PBMCs,





Anti-RANKL antibody (denosumab 7-10) 1 (47) Urine NTX level
Metabolic stimulation E2 Dietary fat reduction 11-14, ER antagonist 
(tamoxifen), aromatase inhibitor
1 (54) Circulating E2 level, 
aromatase level
Insulin biguanide (metformin 15-24) 1 (91)
IGF-1 Anti-IGF-1R antibodies (ganitimumab25,26, 
dalotuzumab27,28, R150729)
2 (98)
Stimulation of tumor 
cell migration
HGF cMET TKIs (cabozantinib30,31, foretinib32,33, 
tivantinib34,35) anti cMET antibody 
(onartuzumab36), anti-HGF antibody 
(AMG102)
3 (114) Circulating HGF level
SDF-1 Anti-SDF-1 antibody, Anti-CXCR4 antibody 
(44717.111), CXCR4 inhibitors (plerixafor, 
CTCE-9908)
4 (118)
Immune modulation PD-1 Anti-PD-1 antibodies (BMS-93655837, 
AMP-51438, AMP-22439, MK-347540), 




CTLA-4 Anti-CTLA4 antibodies (ipilimumab46,47, 
tremelimumab)
3 (153)
TAM Bisphosphonate (zoledronic acid2-6) 4 (152)
Angiogenesis VEGF-A Anti-VEGF-A antibody (bevacizumab48-68), 
anti-VEGFR TKI (sunitinib69-73)
2 (160, 167) 89Zr-bevacizumab PET
Matrix remodeling MMP Various MMP inhibitors (NSC-68355174) 2 (180, 181)
Integrins Integrin inhibitor: cyclized pentapeptide 





LOX Anti-LOXL antibody AB002479 3 (186)
*Level of evidence:
1 Clinical evidence. Treatment effect in breast cancer patients. 
2 Clinical evidence. No treatment effect in breast cancer patients. 
3 Clinical evidence. Treatment effect in non-breast cancer patients. 
4 Preclinical evidence. Treatment effect in breast cancer models. 
5 Preclinical evidence. Treatment effect in non-breast cancer models. 


















































































1,2,3 etc : Currently in clinical trial in breast cancer patients. Clinicaltrials.gov identifier
Search strategies and selection criteria 
Articles for this review were found by searches of PubMed, abstracts american association 
for cancer research (AACR) and american society of clinical oncology (ASCO) and the 
clinicaltrials.gov database by use of the terms ‘breast cancer’, ‘microenvironment’ 
combined with ‘metastasis’ ‘metabolic dysfunction’ ‘migration’ ‘immune cells’ 
‘angiogenesis’ or ‘matrix remodeling’ and combinations of these terms with the selected 
soluble factors. In addition, relevant papers from the reference lists of selected papers 
were included. Only studies written in English were included. 
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Formation of the metastatic niche
The importance of the interaction of the breast cancer cells with their microenvironment 
has long been suggested by the specificity of the metastatic pattern4. In MBC patients, 
metastasis patterns even differ per breast cancer subtype5. In general however, bone is by 
far the most common metastatic site involving 65% of patients with MBC5,13,14. Crucial 
factors involved in the development of bone metastases are transforming growth factor 
(TGF)β and receptor activator of nuclear factor κB ligand (RANKL) (Figure 1A). 
The cytokine TGFβ has tumor suppressive properties in the physiological setting. 
However, during malignant progression, TGFβ signaling promotes growth, progression 
and invasion of the tumor15. Both cancer and cancer associated fibroblasts (CAF)s excrete 
TGFβ by autocrine as well as paracrine secretion, giving rise to a tumor-promoting 
microenvironment (Figure 1A.1 and 1A.2)16,17. Activated TGFβ binds to the TGFβI- and 
TGFβII-receptor (-R) which both induce Smad2 phosphorylation which in turn activates 
transcriptional factors18. 
High circulating plasma levels of TGFβ1, measured by enzyme-linked immunosorbent 
assay, reflected a worse prognosis in 117 and 439 (mainly early stage) primary breast cancer 
patients19,20. TGFβ is highly expressed in the bone tissue surrounding bone metastases21. 
Bisphosphonates are commonly used as supportive treatment in MBC patients with bone 
metastases. In a metastatic mouse model with human breast cancer cells, treatment with 
bisphosphonates reduced TGFβ in the environment of bone metastases22 (Figure 1A.3). 
Three clinical trials studied the effect of the biphosphonate zoledronic acid in the adjuvant 
setting. In the ABCSG-12 trial involving 1,803 patients, disease free survival at 62 months 
was increased from 88% to 92% (hazard ratio (HR) 0.68; 95% confidence interval (CI) 
0.51–0.91; P = 0.009) by the addition of the biphosphonate to endocrine therapy23. The 
ZO-FAST study compared immediate with delayed (after fracture or high risk thereof) 
zoledronic acid administered with adjuvant endocrine therapy. The disease free survival 
increased by immediate zoledronic acid administration from 92% to 95%, (HR 0.588; 95% 
CI 0.361–0.959; P = 0.0314) at 36 months follow up24. In the AZURE trial however, 
amongst 3,360 patients no difference was seen25. In this study the majority of patients 
received chemotherapy rather than endocrine therapy alone. A subgroup analysis in 
patients being postmenopausal for more than 5 years showed an increase in disease free 
survival from 71% to 78.2% (adjusted HR 0.75; 95% CI 0.59 to 0.96; P = 0.02) 5 years 
after randomization. In the NEO-ZOTAC study, amongst 250 human epidermal growth 
factor receptor (HER)2 negative breast cancer patients, no difference in pathologic response 
rate was seen with or without zoledronic acid, administered in the neo-adjuvant setting26. 
A meta-analysis amongst 17,751 from 41 randomized clinical trials compared outcome of 
breast cancer patients with and without adjuvant bisphosphonate treatment and found 
reduction of breast cancer mortality and bone recurrence in post-menopausal patients27. 
Currently, several trials are ongoing to further study the anti-cancer effect of zoledronic 
acid (Table 1). 
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Lowered estrogen levels promote bone turnover activity28, this could lead to the release of 
bisphosphonate from the bone matrix29. In bone-trope xenograft mouse models, more 
bone metastases developed in ovariectomized mice compared to control mice. Zoledronic 
acid treatment reduced tumor growth only in the oophorectomized mice30. These findings 
support the clinical findings and suggest that the development of bone metastasis and the 
effect of zoledronic acid are estradiol (E2) dependent. With regard to other compounds 
that influence TGFβ signaling, only preclinical data are available. In human triple negative 
breast cancer (TNBC) metastatic models in mice, reducing TGFβ signaling, either 
pharmacologically (with pan-TGFβ antibody 1D11 or TGFβ receptor inhibitor Ki26894 or 
LY2109761 or molecularly (with a short hairpin against Smad4), reduced metastases22,31,32 
(Figure 1A.3). However, in a metastatic human luminal breast cancer mouse models, 
targeting TGFβ signaling with 1D11 did not influence metastasis formation after intracardiac 
breast cancer cell injection33. Moreover, deletion of the TgfβII receptor gene in mouse 
mammary epithelial cells increased tumor and pulmonary metastasis formation34. This 
suggests not only that targeting of TGFβ in early phases of tumorigenesis has tumor 
promoting effects, but also that there is likely to be a breast cancer subtype specific aspect 
to this. 
With regard to biomarkers for effective TGFβ targeting , there are limited data available. 
In a syngeneic rat tumor model, ex vivo pSmad2 protein levels in peripheral blood 
mononuclear cells correlated with change in tumor pSmad2 protein levels in response to 
TGFβR tyrosine kinase inhibitor (TKI) LY215729935. A TGFβ response gene signature 
retrieved from primary breast tumors comprising 153 genes was developed to identify 
tumors with high TGFβ signaling activity. In a cohort of 368 samples, tumors positive for 
this gene set did indeed show higher mRNA levels of TGFβ1 and TGFβ236. In estrogen 
receptor (ER) negative tumors, this response signature correlated with recurrent disease in 
the lungs. A study in 12 glioblastoma patients using zirconium-89 (89Zr) labeled GC1008, 
an antibody against active isoforms of TGFβ, for visualization TGFβ showed a 15 times 
higher median standardized uptake value (SUV)max in tumor lesions than in normal brain 
tissue of37. There is one ongoing phase I/II trial in MBC patients with GC1008 in combination 
with local radiotherapy (Table 1) (Figure 1A.3). 
As mentioned previously, another crucial factor involved in the development of bone 
metastases is receptor activator of nuclear factor κB ligand (RANKL). The role of the RANK/
RANKL/osteoprotegerin (OPG) pathway in promoting and sustaining breast cancer bone 
metastases is supported by an increasing amount of preclinical and clinical data. The 
development of bone metastasis is caused by a vicious cycle involving interplay between 
cancer cells and their surroundings (Figure 1A.1 and 1A.2). Cancer cells secrete parathyroid 
hormone-related protein (PTHrP)38. PTHrP subsequently stimulates microenvironmental 
osteoblasts to produce RANKL, which in turn stimulates osteolytic activity by osteoclasts. 
Enhanced osteolysis releases growth factors, such as TGFβ, from the bone matrix. This 
induces tumor growth, and thereby PTHrP excretion, completing the vicious cycle. Data 
from small clinical studies (56 patients) suggest that PTHrP levels, measured 
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Figure 1. Processes in breast cancer microenvironment that promote progression and metastasis. 
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immunohistochemically, are higher in bone metastases compared to primary breast 
cancers39,40. Under physiological circumstances, excessive bone resorption is prevented by 
OPG. OPG is secreted by osteoblasts and competes with RANKL in binding to RANK41 
(Figure 1A.1 and 1A.2). In tumors, OPG can be down regulated via different mechanisms 
such as reduced synthesis42. The RANK/RANKL/OPG axis also plays a role in primary 
breast cancer development. In breast tissue progesterone can induce RANKL expression in 
mammary epithelial cells43, thereby exerting a mitogenic effect. A murine anti RANKL 
antibody reduced tumor formation in a spontaneous mouse mammary tumor model44. 
RANKL treatment of SKBR3 breast cancer cells stimulated proliferation and led to protection 
from cell death in response to irradiation and doxorubicin in vitro45. High RANK and low 
OPG mRNA expression in 295 primary breast cancer tumors was correlated with worse 
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Legend of Figure 1| Processes in breast cancer microenvironment that promote progression and metastasis. 
A | Formation of the metastatic niche. 1) Factors on the tumor cell membrane are transforming growth factor receptor (TGFβR)
I and TGFβRII and the secreted TGFβ and parathyroid hormone-related protein (PTHrP). 2) Factors in the breast cancer 
microenvironment are TGFβ, receptor activator of nuclear factor κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG). 
TGFβ is excreted by cancer associated fibroblasts (CAFs) and is stored in the bone matrix. RANK is expressed by osteoclasts. 
Osteoblasts excrete RANKL and OPG.  3) Targeting options are an anti-TGFβ antibody, TGFβ tyrosine kinase inhibitors (TKI)
s, zoledronic acid and anti-RANKL antibody. 
B | Metabolic stimulation. 1) Factors on the tumor are the cytoplasmic estrogen receptor (ER) and the membrane bound 
insulin receptor ( IR) and insulin-like growth factor 1 receptor ( IGF-1R). 2) Factors in the breast cancer microenvironment are 
inflammation, estradiol (E2), insulin and IGF-1. Obesity leads to inflammation of adipocytes. E2 is excreted by adipocytes. IGF-1 
is secreted by CAFs.  E2, insulin and IGF-1 are also produced elsewhere in the body and reach the breast microenvironment via 
the systemic circulation. 3) Targeting options are dietary fat reduction with our without physical exercise, tamoxifen, aromatase 
inhibitor, metformin and anti IGF-1R antibodies. 
C | Immune modulation. 1) Factor on the tumor cell is membrane bound programmed death ligand (PD- L)1. 2) Factors in 
the breast cancer microenvironment are PD-1, Cytotoxic T lymphocyte-associated antigen (CTLA)-4 and interleukin ( IL)-
12. PD-1 and CTLA-4 are membrane bound proteins on T-cells. IL-12 is secreted by antigen presenting cells (APCs) and 
blocks myeloid derived supressor cells (MDSCs). CD80/86 are membrane bound receptors on the APC. Tumor associated 
macrophages (TAMs) secrete tumor promoting growth factors. 3) Targeting options are PD-L1 antibodies, PD-1 antibodies, 
CTLA-4 antibodies and zoledronic acid. 
D | Stimulation of tumor cell migration. 1) Factors on the tumor cell are cell membrane receptors c-mesenchymal-epithelial 
transition factor (cMET) and chemokine C-X-C motif receptor 4 (CXCR4). 2) Factors in the breast cancer microenvironment are 
hepatocyte growth factor (HGF) and  stromal derived growth factor (SDF)-1. HGF is secreted by CAFs and adipocytes. SDF-1 
is expressed by CAFs and liver, lung and bone. 3) Targeting options are an anti cMET antibody, cMET TKIs, an HGF antibody, 
SDF-1- antibodies and CXCR4 antagonists. 
E | Angiogenesis. 1) The factor of the tumor cell is vascular endothelial growth factor (VEGF)-A, which is excreted. 2) Factors 
in the breast cancer microenvironment are the ligand VEGF-A and the receptors VEGF-R and platelet derived growth factor 
receptor (PDFGR). VEGF is also being excreted by TAMs. VEGFR and PDFGR are expressed by endothelial cells. 3) Targeting 
options are an VEGF antibody and a VEGFR and PDFGR TKI. 
F | Matrix remodeling. 1) Factors on the tumor cell are the membrane bound integrin A and B and the excreted matrix 
metalloproteases (MMPs), lysyl oxidases (LOX) and LOX ligand (LOXL)2. 2) Factors in the breast cancer microenvironment 
are the extracellular matrix (ECM), integrins, MMPs, LOX and LOXL2. Integrins are bound to the ECM. MMPs, LOX and LOXL2 
are secreted by CAFs. 3) Targeting options are an anti-integrin antibody, an integrin inhibitor, various MMP inhibitors and an 
anti-LOXL2 antibody. 
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overall survival46. High RANK expression, measured by immunohistochemistry in 93 
breast cancer samples, was associated with earlier onset of bone metastases development46. 
The importance of RANKL in the development of skeletal related events has been 
proven with denosumab, a monoclonal antibody that binds human RANKL to inhibit bone 
destruction47 (Figure 1A.3). A randomized double blind study in 2,046 MBC patients with 
at least one bone metastasis, showed superiority of denosumab compared to zoledronic 
acid in delaying time to first on-study skeletal-related event48. Time to disease progression, 
overall survival and adverse events rates were similar between these groups. Denosumab is 
now part of standard clinical care to supplement the treatment of bone metastasis in MBC. 
Clinical trials are ongoing to study the anti-cancer effect of denosumab (Table 1). 
Data on biomarkers for targeting RANKL are limited, and assessment is mostly based 
on clinical grounds: skeletal related events, recurrence and death. Denosumab treatment 
decreased urine N-terminal telopeptide levels in MBC patients with bone metastases49. 
However, serum levels RANK/RANKL/OPG levels did not correlate with these endpoints in 
30 MBC patients treated with bisphosphonates50. 
In conclusion, bone is clinically the most seductive environment for breast cancer. The 
formation of the metastatic niche by the microenvironment there, is affected by TGFβ and 
RANK/RANKL/OPG signaling. Standard treatment options in MBC that may at least in part 
exert their effect by influencing these factors are bisphosphonates and denosumab. TGFβ 




The metabolic environment can profoundly affect breast cancer behavior. Microenvironmental 
factors contributing in the process of metabolic stimulation of breast cancer are obesity and 
metabolic dysfunction. Soluble factors involved in this are E2, insulin and insulin-like 
growth factor (IGF)-151 (Figure 1B). 
Obesity increases the risk of death due to breast cancer. In a prospective, population 
based study in almost 500,000 women, the relative risk of breast cancer death was 2.1 in 
obese women with a body mass index (BMI) of at least 40 compared to normal weight 
women52. Moreover in patients with ER positive breast cancer, obesity is a risk factor for 
recurrence of breast cancer53 and development of metastases54. Furthermore, dietary fat 
reduction seems to prolong disease free survival in women with resected breast cancers 
independently of ER presence (Figure 1B.3). In a group of 2,437 women with resected 
early stage breast cancer, patients were randomized between dietary intervention and 
control groups. In the dietary intervention group, 9.8% relapsed compared to 12.4% in the 
control group (P = 0.034)55. A preclinical study described a link between high fat diet and 
breast cancer growth56. The cholesterol metabolite named 27-hydroxycholesterol, which 
mimics estrogen in certain tissues, resulted in faster tumor growth and more metastasis 
formation after administration to MMTV-PyMT mice. On a high fat, high cholesterol diet 
these mice showed also more rapid tumor growth compared to mice on a normal diet. 
Clinical trials are ongoing to study the anti-cancer effect of dietary fat reduction (Table 1). 
In a prospective observational study, physical activity equivalent to 3-5 hours walking a 
week improved survival in 2,987 breast cancer patients57. The exact mechanism behind 
this effect remains to be speculated about58. 
The mechanisms linking obesity and breast cancer development and outcome are 
multifactorial involving inflammation, hormonal inbalance and metabolic dysfunction. 
Obesity leads to inflammation of adipose tissue which is characterized by necrotic 
adipocytes surrounded by macrophages59 and the level of breast inflammation is correlated 
with BMI60 (Figure 1B.2). Chronic inflammation is related to the development of various 
cancer types61. In two case-control studies with in total almost 2000 post-menopausal 
women, systemic levels of the aspecific inflammatory marker C-reactive protein (CRP) or 
soluble tumor necrosis factor receptor (sTNFR)2 were associated with overweight and 
increased breast cancer risk62,63. In a randomized trial amongst 439 obese and overweight 
women, weight loss alone or in combination with exercise resulted in reduction of the 
inflammatory biomarkers IL-6, serum amyloid A and high sensitivity-CRP compared to 
baseline and compared to controls64. 
Presumably the most powerful factor by which elevated body weight promotes breast 
cancer, is E265. The conversion from testosterone by aromatase enzyme cytochrome p450 
leads to the production of E266. During the fertile phase E2 is primarily produced in the 
ovaries, while various cells including adipocytes in the breast, excrete E2 in postmenopausal 
women67,68. E2 binds to the nuclear ER present on breast cancer cells and CAFs69-72 
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(Figure 1B.1 and 1B.2), leading to cancer cell proliferation. Increased aromatase activity in 
fat tissue leads to elevated E2 levels in breast tumors compared to normal breast tissue68. 
Interestingly, high BMI in postmenopausal women is associated with higher aromatase 
activity leading to high E2 levels and augmented breast cancer risk65. Weight loss alone or 
in combination with exercise, on the other hand, reduced systemic E2 levels in overweight 
patients73. This phenomenon is proposed as a cause for the worse prognosis observed in 
women who experience weight gain after breast cancer treatment74. The effect of physical 
exercise alone on E2 levels is inconsistent, although modest at most73,75. E2 signaling can 
be targeted using aromatase inhibitors or ER antagonists (such as fulvestrant or tamoxifen) 
(Figure 1B.3). Studies comparing treatment efficacy of estrogen targeting between obese 
and normal weight patients showed contradicting results54,76. As can be expected, ER 
positive tumor cells can indirectly be influenced by oophorectomy. Lowering circulating E2 
by oophorectomy in unaffected BRCA1 mutation carriers also reduces the risk of breast 
cancer by 56%77. This is very intriguing as the majority of BRCA1 associated breast cancers 
is ER negative78. The discrepancy might be explained by E2 responsiveness of luminal 
progenitor cells of BRCA1 associated basal tumors79. This may explain the reduced 
incidence of secondary breast cancers by tamoxifen in BRCA1 or BRCA2 carriers with 
breast cancer (OR= 0.50, 95% CI: 0.28-0.89)77. Another potential explanation is the fact 
that in the breast, ER is expressed in epithelial- as well as in stromal cells and stromal ER 
expression can affect tumor growth80-82. 
In addition to the endocrine importance of adipose tissue in the breast, obesity is 
related to metabolic dysfunction, which can also affect tumor progression83,84. In obesity, 
non-esterified fatty acids compete with glucose as a metabolic fuel, inducing insulin 
resistance leading to high glucose and insulin levels. Insulin is being produced by pancreatic 
ß-cells and binds to the insulin receptor on the cell membrane of nearly all cell types 
(Figure 1B.1 and 1B.2). Insulin binding to the insulin receptor on breast cancer cells 
activates the PI3K and MAPK signaling pathways and results in a cascade of proliferative 
and anti-apoptotic events. The PI3K pathway mediates the glucose regulatory effects of 
insulin but is inhibited in insulin resistance and, therefore, hyperinsulinemia, leading to 
increased signal transduction, is required to restore normal PI3K pathway activity. Since 
signaling via the MAPK pathway is preserved despite insulin resistance, high insulin levels 
in the microenvironment of breast cancer cells lead to hyperactivation of this pathway and 
enhanced cellular proliferation85. In insulin resistance and diabetes mellitus in patients, 
insulin responsive tissues, such as skeletal muscle, become insulin resistant, stimulating 
insulin production. Epithelial cells including breast cancer cells probably remain relatively 
insulin sensitive and the consequent increased insulin-mediated signaling can lead to 
enhanced proliferation in cell line models86. In animal models and humans, both insulin 
resistance and exogenous insulin injections have been associated with an increased risk of 
cancer and cancer recurrence87. Insulin and hyperinsulinemia can also promote 
tumorigenesis indirectly by influencing the levels of other modulators, such as IGFs, sex 
hormones, inflammatory processes and adipokines88. Insulin resistance and 
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hyperinsulinemia suppress the production of sex hormone-binding globulin by the liver89. 
This can lead to increased availability of free sex hormones favoring breast cancer 
development and progression90. 
Metformin, which belongs to the biguanide class of oral hypoglycemic agents, is 
prescribed to over 120 million type 2 diabetic patients worldwide. It reduces insulin 
resistance, and leads to lower insulin and glucose levels which may also reduce tumor cell 
growth (Figure 1B.3). Metformin indeed diminishes the growth of breast cancer cells in 
vitro91. Retrospectively, patients with breast cancer who received neoadjuvant chemotherapy 
were studied; diabetic cancer patients receiving metformin during their neoadjuvant 
chemotherapy had a higher pathologic complete response rate compared to diabetic 
patients not receiving metformin (24% vs 8%; P = 0.007)92. Several trials are ongoing to 
further study the anti-cancer effect of metformin (Table 1). 
A related metabolic factor is IGF-1, which is produced by the liver as well as by CAFs93 
(Figure 1B.1 and 1B.2). IGF-1 activates, by binding to its receptor IGF-1R at the tumor cell 
membrane, the PI3K/AKT pathway. AKT is phosphorylated which leads to cell proliferation 
and inhibition of apoptosis of the tumor cell. Insulin resistance can result in high IGF-1 
levels through various mechanisms94. High IGF-1 levels in the microenvironment promote 
cancer cell growth. IGF-1R is overexpressed in numerous solid tumors including breast 
cancer95, and is implicated (in both clinical and preclinical studies) in resistance to 
hormonal therapy and human HER2 targeting95,96. BRCA1 mutation carriers primarily 
develop TNBC (80%), and these tumors express elevated IGF-1R levels. Mutated BRCA1 
fails to suppress IGF-1R, whereas tumors with wild-type BRCA1 are able to suppress IGF-
1R97. In effect, the large majority of TNBCs express cytoplasmic and membranous IGF-
1R95,98, which is associated with a worse prognosis95. By targeting IGF-1R on the tumor 
cells, the binding of IGF-1 to its receptor is blocked (Figure 1B.3). Despite a strong rationale 
to intervene with IGF1-R, clinical trials in (breast) cancer with anti IGF-1R antibodies have 
until now failed to show significant clinical relevance99. Clinical trials studying the effect of 
IGF-1R inhibition in breast cancer are ongoing (Table 1). 
In conclusion, metabolic stimulation of breast cancer is induced by obesity, E2, insulin 
and IGF-1 in the breast cancer microenvironment. Intervention strategies, including weight 
and dietary fat reduction and metformin treatment, have proven to benefit breast cancer 
patients. No clinical benefit from IGF-1R inhibitors has been seen so far. Clinical trials 
studying inhibition of this factor are ongoing. 
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Stimulation of tumor cell migration
After tumor cells have invaded into their surroundings, the next step of tumor progression 
is migration to and through the circulation. The breast cancer microenvironment contains 
several factors that stimulate tumor cell migration, including hepatocyte growth factor 
(HGF) and stromal derived growth factor (SDF-1) (Figure 1D). 
HGF is a soluble factor that is being secreted by CAFs and adipocytes and binds to the 
c-mesenchymal-epithelial transition factor (cMET) tyrosine kinase receptor on cancer cells 
100 (Figure 1D.1 and 1D.2). Binding of the cMET receptor triggers several downstream 
pathways in tumor cells, including MAPK and PI3K, inducing proliferation and migration101. 
Transcription of both HGF and cMET is induced by several stromal cytokines such as 
interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-α and TGF-β102. High cMET 
expression determined immunohistochemically in 930 and 330 primary breast tumors, 
respectively, was more frequently present in deceased or metastasized patients103 and 
correlated with worse disease related survival104. Also, high cMET expression, based on 
protein arrays from lysates of 257 fine needle aspirates of primary breast cancers, is 
associated with worse disease free and overall survival105. Presurgical serum HGF levels 
were 1.5 fold higher in 124 mainly stage II and III breast cancer patients compared to 35 
women with benign breast tumors106. 
HGF added to breast cancer cells induced migration and invasion in vitro107,108. In vivo, 
lung metastasis formation was enhanced when tumor cells were incubated with HGF 
before inoculation109. Transgenic mice in which HGF expression was elevated by HGF 
cDNA in their mammary epithelium, developed invasive mammary tumors and pulmonary 
metastases110. Moreover, HGF can play a role in sensitivity to certain drugs. HGF lowered 
sensitivity to the HER2 and Epidermal Growth Factor Receptor (EGFR)1 TKI lapatinib in 
HER2 positive breast cancer cells111. Inhibiting HGF excretion by fibroblasts studied with 
hammerhead ribozymes reduced invasiveness of breast cancer cells in vitro112,113. Using the 
same technique, cMET inhibition reduced migration and invasion of breast cancer cells in 
vitro in response to HGF112. In addition, growth of human breast cancer xenografts co-
injected with cells from a human fetal fibroblast cell line in mouse models was decreased 
when HGF excretion by these fibroblasts was inhibited112,113. Tivantinib, a selective cMET 
inhibitor, reduced bone metastasis formation in mice after injection of MDA-MB-231 
tumor cells into the systemic circulation114. 
These results have prompted clinical trials with compounds targeting the HGF/cMET 
axis (Figure 1D.3). In a phase 1 trial with the TKI tivantinib, 14 out of 51 advanced solid 
tumor patients had stable disease for over 4 months115. Two other TKIs, cabozantinib and 
foretinib (both against vascular endothelial growth factor receptor (VEGFR)2 and cMET), 
are currently being tested in breast cancer patients with ER positive and HER2 overexpressing 
tumors (Table 1). Phase 2 trials are ongoing in TNBC patients with tivantinib, cabozantinib, 
foretinib and the cMET monovalent antibody onartuzumab (Table 1). With regard to the 
prediction of response to anti-cMET therapy, in a human glioblastoma xenograft in mice, 
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the level of autocrine HGF excretion was predictive for the response to anti cMET therapy 
by a TKI116. For molecular imaging, both cMET and HGF can be visualised pre-clinically. 
Mouse agonistic human cMET antibody DN30 was radiolabeled with 89Zr. In nude mice 
bearing a human gastric- or head-and-neck cancer cell line xenograft, 89Zr-DN30 injection 
resulted in a maximum tumor to blood ratio of 5117. Anti-HGF nanobodies (1E2-Alb8 and 
6E10-Alb8) were labeled with 89Zr and used as a positron emission tomography (PET) 
tracer in nude mice bearing human glioblastoma xenografts. Tumor uptake of the tracer 
remained stable, while blood levels of the tracer gradually decreased over time, suggesting 
specific tumor uptake. The nanobodies inhibited tumor growth118. With regard to 
biomarkers for evaluating the effect of cMET of HGF targeting, no clinical molecular 
imaging data are available.
SDF-1 (also known as CXCL12) is produced by CAFs and acts as chemo-attractant for 
tumor cells expressing chemokine C-X-C motif receptor 4 (CXCR4)119,120 (Figure 1D.1 and 
1D.2). Organs expressing SDF-1, such as lung, bone marrow and liver, can thus lure 
CXCR4 expressing tumor cells to migrate towards them121. High SDF-1 expression 
determined immunohistochemically in breast cancer tissue of stage I-III patients, was 
prognostic for worse disease free- and overall survival in three retrospective studies 
involving a total of 628 patients122-124. The correlation between CXCR4 expression in breast 
cancer tissue and patient outcome has been studied frequently, with contradictory 
results125-127. Targeting SDF-1 or CXCR4 with antibodies or peptide inhibitors decreased 
breast cancer cell motility in vitro and reduced tumor growth and metastasis formation in 
vivo119,128 (Figure 1D.3). This makes clinical data with the CXCR4 antagonist plerixafor also 
of interest for breast cancer though no clinical data for breast cancer exists to date. A phase 
I/II clinical trial using plerixafor, administered in addition to chemotherapy showed the 
safety of this combination in 46 relapsed acute myeloid leukemia patients129. To compare 
tumor levels of CXCR4 with the physiological expression, several CXCR4 targeting imaging 
agents have been developed in the preclinical setting (reviewed in130,131). Small molecules, 
antibodies and peptides directed against CXCR4 have been radiolabeled and show CXCR4 
expression level dependent tumor uptake in several xenograft mouse models, including 
breast tumors132-136. None of these tracers have reached the clinical setting at this point. 
In conclusion, stimulation of tumor cell migration by the microenvironment involves 
HGF and SDF-1 signaling. Intervention strategies including cMET, HGF and CXCR4 
inhibitory agents are moving into the clinical arena in an investigational setting. 
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Immune response modulation 
The immune system plays a major role in cancer development. Although the host immune 
system should act against tumor cells, various factors in the tumor microenvironment in 
fact act in favor of the cancer cells, by modulating the this immune response. In breast 
cancer, key immunological players are T-cells, immune checkpoint receptors and tumor 
associated macrophages (TAM)s (Figure 1C). 
T-cells can recognize and destroy cancer cells. Infiltration by memory T-cells seen in a large 
cohort of primary tumors, including breast cancer, was the strongest positive prognostic 
factor in favor of disease free survival and overall survival at all disease stages137. In HER+ 
or TNBC breast cancer patients neoadjuvantly treated with chemotherapy with our without 
trastuzumab, the presence of TILs was associated with higher treatment response138,139. 
Myeloid-derived suppressor cells (MDSC) and immune checkpoint receptors suppress 
T-cell activation in the microenvironment. IL-12 is excreted by dendritic cells and promotes 
antitumor immune response and blocks MDSC 140 (Figure 1C.2). Programmed cell death 
(PD)-1 is present on T-cells and functions as an immune checkpoint receptor which plays 
a role in tumor progression141 (Figure 1C.1 and 1C.2). After binding to its ligand PD-L1, 
that is present on tumor cells, the T-cell is inactivated, enabling tumor cells to evade the 
host’s immune system142. PD-L1 is electively expressed by many solid tumors and by 
isolated tumor cells within the microenvironment in response to inflammatory stimuli. 
Blockade of the interaction between PD-1 and PD-L1 potentiates immune response in vitro. 
In immunocompetent MMTV-ErbB-2 transgenic mice PD-1 antibody improved the 
therapeutic activity of anti-HER2 therapy143. Half of 44 human breast cancer specimens 
showed PD-L1 expression immunohistochemically. PD-L1 expression in these specimens 
correlated with a more aggressive tumor histology144. The presence of PD-1 positive tumor 
infiltrating lymphocytes, measured by immunohistochemistry in 660 breast cancer samples 
was correlated with lower overall patient survival145. Cytotoxic T lymphocyte-associated 
antigen (CTLA)-4 is also present on T-cells and binds to CD80 on cancer cells, thereby 
transmitting an inhibitory to the T-cell (Figure 1C.1 and 1C.2). Blocking of CTLA-4 by an 
inhibitory antibody lead to tumor regression in vivo146. CTLA-4 levels, measured by 
immunohistochemistry and on mRNA level in 90 samples, were higher in breast cancer 
tissue compared to normal breast tissue147. Another group of immune cells are TAMs 
derived from CD34+ bone marrow progenitors. TAMs can increase the survival and 
proliferative capacity of cancer cells, by secreting growth factors (Figure 1C.1 and 1C.2). 
In breast cancer, the presence of TAMs is associated with a worse prognosis148.
The importance of targeting the immunological support of tumor cells by the 
microenvironment is increasingly supported by clinical data. In a phase I trial involving 
various HER2 positive metastatic cancers, including seven patients with MBC, patients 
received a combination of paclitaxel, trastuzumab and IL-12. Among the seven MBC 
patients, one experienced a complete response and two a partial response149. There was 
increased activation of extracellular signal-regulated kinases in peripheral blood 
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mononuclear cells and increased levels of interferon (IFN)γ and several chemokines in 
patients achieving a clinical benefit compared to patients with progressive disease149. 
Whether these factors may be useful future biomarkers for response prediction will have to 
be shown in larger trials. Anti-PD-L1 antibody BMS-936559 was administered to 207 
extensively pretreated patients, including four with breast cancer (Figure 1C.3). The overall 
objective response rate was 13% and 34% had prolonged disease stabilization150. PD-L1 
expression, measured immunohistochemically, correlated to clinical activity of anti PD-1 as 
well as anti PD-L1 antibodies151. However, patients without PD-L1 staining still showed a 
response rate of 13-17%, compared to 39%-44% of patients with PD-L1 expression151,152. 
Several phase 1 trials with PD-1 and PD-L1 antibodies in solid cancer patients are ongoing 
(Table 1). High PD-L1 gene expression levels in patients treated neoadjuvantly with 
trastuzumab, pertuzumab or both were associated with a lower complete response rate. 
These results provide a rationale for combining HER2-targeted treatments with immune-
modulating agents and may allow the prediction of treatment benefit153. Tremelimumab 
and ipilimumab block the activity of T-cell suppressor CTLA-4 (Figure 1C.3). In a phase I 
study in which 26 MBC patients received tremelimumab and exemestane, 11 experienced 
stable disease as best response154. Ipilimumab studies in MBC patients are ongoing (Table 
1). TAMs are derived from the same cell lineage as osteoclasts, therefore the effect of 
bisphosphonates on TAMs was studied. In mice transgenic for HER2, the number of TAMs 
was lower in the tumor microenvironment in parallel with the decrease in tumor 
vascularization after bisphosphonate administration (reviewed in155) (Figure 1C.3).
In conclusion, key players in the immunological microenvironment of breast cancer are 
T-cells, IL-12, immune checkpoint receptors and TAMs. Modulation of adequate T cell 
response to breast cancer is effected by CTLA-4 and PD-1. Targeting this process, by 
compounds such as IL12, tremelimumab, ipilimumab and PD-1/PD-L1 inhibitors, is a 
promising strategy in breast cancer treatment 
Angiogenesis
The tumor microenvironment instigates new vessel formation in response to pro-angiogenic 
factors secreted by cancer cells156 (Figure 1E). These tumor vessels show leakiness and a 
chaotic structure. As a result, angiogenic stimuli are increased which leads to an even more 
defective vascular system. In the earliest breast cancer stages, angiogenesis is already 
implicated. VEGF-A is secreted by cancer cells and TAMs and binds to the VEFGRs on 
endothelial cells156,157 (Figure 1E.1 and 1E.2). VEGF-A expression in normal glandular 
epithelial structures of the human breast is lower than in (pre)malignant lesions. Expression 
increased with tumor dedifferentiation (mean number of VEGF-A positive cells 2.5% ± 
0.4% in normal lobules versus 10.4% ± 6.6% malignant lesions, P < 0.001)158. 
In vivo experiments using different non-breast cancer human xenografts in mice showed 
anti-tumor effect of a monoclonal murine anti-human VEGF-A antibody159. Bevacizumab, 
the most widely used anti-angiogenic drug, is an anti-VEGF-A humanized monoclonal 
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antibody160 (Figure 1E.3). A meta-analysis of 7 trials involving 4,032 MBC patients, studied 
the effect of combining bevacizumab with first line chemotherapeutic drugs and showed a 
progression free survival prolongation of 1.4 to 5.8 months (HR 0.67; 95% CI 0.61 to 
0.73) while overall survival was not increased161. In the RIBBON-2 trial bevacizumab was 
combined with standard chemotherapy compared to chemotherapy alone as second line 
treatment in patients with HER2 negative MBC162. Progression free survival was prolonged 
from 5.1 to 7.2 months, but again overall survival was not affected. A subgroup analysis of 
the RIBBON-2 trial in TNBC patients showed a trend towards increased overall survival163. 
Whether there is truly a benefit with bevacizumab for this subtype in the metastatic setting 
is currently being investigated (Table 1). The negative BEATRICE trial does not support a 
role for bevacizumab in the adjuvant treatment for TNBC patients164. Also, no additional 
value was found when bevacizumab was combined with either anti-HER2 or endocrine 
therapy in a subset of HER2 positive and ER positive MBC patients165,166. Multiple phase III 
trials with bevacizumab in breast cancer patients are still ongoing (Table 1). 
Anti-angiogenic agent sunitinib is a TKI against platelet derived growth factor receptors 
(PDGFR) and VEGFRs (Figure 1E.3). In MBC patients, sunitinib did not prolong progression 
free survival in phase III trials, and monotherapy sunitinib had an inferior progression free 
survival compared to capecitabine167,168. Clinical trials with sunitinib in breast cancer 
patients are ongoing. However, so far none of these anti-angiogenic drugs seem to play a 
clinically relevant role in any of the studied breast cancer subgroups. 
While the clinical relevance of targeting VEGF in breast cancer is limited, measuring 
angiogenic factors may be used for tumor identification of a susceptible subtype. Plasma 
VEGF-A levels showed no clear relationship with clinical effect of angiogenesis 
inhibitors169-171. However, circulating levels of VEGF-A, may not reflect what is happening 
at the level of the tumor since VEGF-A binds locally to the ECM172. By radiolabeling the 
anti-VEGF antibody bevacizumab with 89Zr, VEGF can be visualized with PET. Preclinically, 
there was tumor specific uptake in human breast and ovarian xenografts in mice173,174. In 
patients, 89Zr-bevacizumab uptake on PET was shown in 25 of 26 primary breast tumors175. 
Interestingly, 89Zr-bevacizumab uptake in the primary breast tumors was relatively low, 
compared to tumor uptake in a series of 22 metastatic renal cell cancers (mean SUVmax 1.85 
vs 10.1)175,176. This difference in VEGF-A tumor levels between renal cell and breast cancer 
lesions, may possibly be related to the difference in efficacy of targeting angiogenesis in 
these tumor types.
In conclusion, angiogenesis in the microenvironment to support breast cancer growth, 
is effected by VEGF-A and its receptors. Targeting strategies, including bevacizumab and 
sunitinib, have been studied in breast cancer; however, so far limited effects have been seen 
for this therapeutic strategy in breast cancer treatment.
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Extracellular matrix remodeling 
The ECM prevents tumor cells from invading the surrounding tissues, and remodeling of 
the ECM is therefore an obvious process by which the microenvironment might support 
tumor cells. Numerous factors are involved in this process, including integrins, lysyl 
oxidase (LOX) and matrix metalloproteases (MMPs) (Figure 1F). 
Integrins at the tumor cell membrane are a family of heterodimeric, transmembrane 
glycoproteins consisting of one α and one β subunit. Each family member binds multiple 
ECM ligands which activates intracellular signaling pathways177 (Figure 1F.1 and 1F.2). 
MMPs are a family of (secreted or membrane bound) proteolytic enzymes which are 
expressed by a variety of cells including cancer cells and CAFs and have the ability to 
degrade ECM components178-180 (Figure 1F.1 and 1F.2). Despite a strong rationale for 
targeting factors involved in ECM remodeling, clinical trials with anti-integrin and anti-
MMP strategies have so far failed to show meaningful results181-186 (Figure 1F). Several 
phase I studies with a MMP inhibitor and integrin inhibitors are ongoing in metastatic solid 
cancer patients (Table 1). 
A potential alternative might be to target LOX. Members of the LOX family are secreted 
by cancer and stromal cells in response to hypoxia and modify the ECM (Figure 1F.1 and 
1F.2). LOX crosslinks collagen IV in the basement membrane of the ECM, recruits CD11b+ 
cells to distant metastatic sites and induces expression of MMPs. Both up-and down 
regulation of LOX family members have been associated with cancer progression. This 
paradoxical role of the LOX family is possibly due to their multiple temporal and spatial 
expression patterns, which may confer differential functions187. However, more evidence 
suggests that the extracellular activity of these proteins in remodeling the ECM facilitates 
tumor cell invasion and metastasis. Preclinical models showed a decrease in metastases 
formation after inhibition of LOX and LOXL2187, without affecting tumor growth. The 
LOXL2 antibody, AB0024 is currently tested in a phase 1 clinical trial (Table 1) (Figure 
1F.3). 
In conclusion, extracellular matrix remodeling by the microenvironment is effected by 
integrins, LOX and MMPs. Targeting strategies including anti-integrin, anti-MMP and up-
and down regulation of LOX have so far not been successful in supporting the relevance of 
this process in breast cancer.
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Discussion and future perspectives
The focus of this review was to describe the current knowledge of processes involved in the 
breast cancer microenvironment, and how these processes affect breast cancer progression 
and metastasis. We described the formation of the metastatic niche, metabolic stimulation, 
stimulation of tumor cell migration, immune modulation, angiogenesis and matrix 
remodeling. Increasing evidence is supporting the significance of targeting the breast 
cancer microenvironment. However, different levels of evidence for targeting the described 
processes are apparent. Targeting the process of formation of the metastatic niche and 
metabolic stimulation by the breast cancer microenvironment, is already showing clinical 
efficacy. Intervening with stimulation of tumor cell migration and immune modulation by 
the microenvironment, is an upcoming field of great interest and research. In contrast, 
targeting of microenvironmental angiogenesis or matrix remodeling appears to be of limited 
clinical relevance in breast cancer treatment so far. 
To optimize targeting the microenvironment for maximal anti-cancer effect, more 
detailed knowledge of the interaction between environment and cancer is needed. 
Preclinical models that allow investigation of this interaction in a species specific manner 
are currently in development. Furthermore, as many of the described processes take place 
in parallel, combining agents directed at multiple microenvironmental factors, administered 
in combination with standard anti-cancer directed treatments such as chemotherapy, may 
ensure the best clinical result. In addition, differences between breast cancer subtypes are 
becoming more and more apparent188 and selecting the appropriate study population could 
maximize treatment results. 
In view of the fact that microenvironmental factors usually do not consistently have a 
“good” or “bad” impact during cancer progression, it is vital to study the optimal timing of 
administering microenvironment targeting agents in future studies. With regard to 
predictive markers for treatment response, tissue and blood assessments may be suitable 
for this purpose. However, these are static measurements that may not suit the dynamics of 
targeting microenvironment-cancer interactions. Molecular imaging, although not generally 
available, can provide local real time information about the in vivo interaction of the tumor 
and its microenvironment. As PET imaging results in whole body images, it may also offer 
information regarding intra- and inter lesion heterogeneity155,189
In summary, targeting the breast cancer microenvironment is an upcoming field of 
research. For some of the processes involved in the tumor-stroma interaction, clinical 
evidence for useful intervention is already present, supporting the concept of targeting 
these processes. Further optimization of this approach is warranted, with regard to 
combinations of agents, timing, improved knowledge of breast cancer subtype specific- 
aspects, and predictive markers, to improve this approach for comprehensive 
implementation in breast cancer care. 
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Abstract
Purpose: Human epidermal growth factor receptor (HER)2 imaging with radiolabeled 
trastuzumab might support HER2 targeted therapy. It is however frequently questioned 
whether HER2 imaging is also possible during trastuzumab treatment as the receptor might 
be saturated. Here, we studied the effect of trastuzumab treatment on 111In-trastuzumab 
uptake. 
Procedures: Patients received trastuzumab weekly and paclitaxel 3-weekly. 111In-
trastuzumab was injected on day 1 of cycle 1 and day 15 of cycle 4. Whole-body planar 
scintigraphy was acquired on different time points post injection. Tumor uptake and organ 
distribution between first and repeated scan series were calculated via residence times. 
Results: 25 tumor lesions in 12 patients were visualized on both scintigraphy series. 
Tumor uptake decreased (19.6%; P = 0.03). Residence times of normal organs remained 
similar, except the cardiac blood pool (+16.3%; P = 0.014). 
Conclusion: Trastuzumab treatment decreases tumor 111In-trastuzumab uptake around 




Tumor overexpression or amplification of the human epidermal growth factor receptor 
(HER)2 occurs in 25% to 30% of patients with breast cancer and is involved in tumor cell 
survival, proliferation, maturation, dissemination and angiogenesis, and has anti-apoptotic 
effects1,2. Trastuzumab is a humanized monoclonal antibody approved for treatment in the 
(neo)adjuvant and metastatic setting of patients with HER2 positive breast cancer. Addition 
of trastuzumab to chemotherapy results in an increased time to disease progression, higher 
objective response rates, and longer overall survival3,4. Accurate characterization of HER2 
expression is essential for optimal therapy. Therefore, the HER2 status should be assessed 
in all patients with breast cancer to identify HER2 positive tumors. Ex vivo methods to 
determine the HER2 status of the primary tumor are immunohistochemistry (IHC) and 
fluorescence in-situ hybridization (FISH). These methods require biopsies which are not 
always feasible. Furthermore, sampling error cannot be ruled out with repeated biopsies. 
This is particularly relevant in view of possible heterogeneous HER2 expression. 
Heterogeneity can exist between the primary tumor and the metastases5, between different 
metastases and within a metastasis. Discordance of HER2 expression between primary 
tumors and metastases, as measured by IHC and/or FISH, varies between 10-24%6,7. Loss 
or gain of HER2 expression can have clear therapeutic consequences, as patients with 
HER2 positive lesions benefit from anti-HER2 therapy3,8. This underlines the necessity to 
accurately assess HER2 status during the course of metastatic breast cancer. Non-invasive 
determination of HER2 expression can potentially be performed with molecular imaging. 
This might facilitate selection of patients for HER2 targeted therapy and assess the 
immediate response to therapeutic interventions. In the clinical setting HER2 imaging may 
be performed with trastuzumab radiolabelled with the γ-emitter indium-111 (111In) and 
with the positron emission tomography (PET) isotope zirconium-89 (89Zr)9,10. Experience 
with HER2 imaging increases, however this comes with the frequently asked question 
whether and how trastuzumab treatment affects the HER2 scan as the receptor may be 
already occupied. We previously reported about 111In-trastuzumab scintigraphy in 17 
patients with HER2 over-expressing metastatic breast cancer after the first loading dose of 
trastuzumab9. Part of these patients underwent a second scintigraphy procedure during 
treatment. This gives us the unique opportunity to assess the feasibility of HER2 imaging 
in patients while on trastuzumab treatment.
Therefore, the aim of this study is to quantitatively describe the biodistribution and 
uptake of 111In-trastuzumab over time during 14 weeks of trastuzumab treatment. 
 
111IN-TRASTUZUMAB SCINTIGRAPHY IN HER2 POSITIVE METASTATIC BREAST CANCER PATIENTS 





Eligibility criteria were described earlier9. In short, included patients were women with 
histological confirmed HER2 positive metastatic breast cancer eligible for treatment with 
paclitaxel and trastuzumab. After the loading dose of 4 mg/kg, trastuzumab was 
administered as a weekly intravenous infusion of 2 mg/kg. Paclitaxel (175 mg/m2) was 
administered intravenously in 4 hours as an intravenous infusion, once every 3 weeks for 
6 cycles. The study was approved by the local medical ethical committee. All patients 
provided written informed consent.
111In-trastuzumab Scintigraphy 
Trastuzumab was radiolabelled with indium-111 (111In), using as described previously11. A 
total of 100 - 150 MBq 5 mg 111In-trastuzumab was injected intravenously, within 24 hours 
after the infusion of the trastuzumab loading dose at baseline. 111In-trastuzumab injection 
was repeated after the trastuzumab dose on day 15 of the fourth cycle (14 weeks later). 
Whole body planar scintigraphy was performed at 4 different time points at 15 minutes, 
24, 72 - 96 and 168 hours post injection (Figure 1). A dual-head Multispect-2 camera or 
dual-head E.Cam camera was used (Siemens, CTI, Knoxville, TN) as previous described9. 
Scintigraphy series for each patient series were performed on the same camera. Only 
patients with a first and repeated scintigraphy series were analyzed. For quality control of 
dosimetry calculations an aliquot of dose containing a known fraction of the injected 
radioactivity was positioned adjacent to the patient during scanning. 
111In-trastuzumab Tumor Uptake, Organ Distribution and Radiation Dosimetry 
The uptake of 111In-trastuzumab was determined by calculating residence times for tumors 
and organs. Residence time was defined as the area under the curve of radioactivity versus 
time (time-activity curve) and was calculated using the SPRIND software package12. The set 
of organs for which the residence times were calculated was limited to those organs that 
were clearly distinguishable on the planar scintigraphy. The residence time was in addition 
used for internal radiation dose assessment according to the medical internal radiation dose 
(MIRD) scheme13. The radiation absorbed dose for all organs of interest as well as the 
effective dose was determined in accordance with the International Commission on 
Radiological Protection publication 60 (ICRP-60)14. The estimated dose (ED) was calculated 
as a weighted mean of the absorbed radiation dose over organs defined within the ICRP 
framework. Organ level internal radiation dose calculations using the MIRD and ICRP-60 
are implemented in the OLINDA/EXM software package15. OLINDA/EXM incorporates a set 
of phantoms (adult male, adult female etc) that define the size of organs and the geometric 
relation between them. This determines the contribution from radioactivity in one organ to 
the absorbed dose in another organ. The quantitative results of the scintigraphy series were 




Data are presented as mean ± standard deviation (SD). Statistical analysis was performed 
using the Wilcoxon test for paired non-parametric data (SPSS, version 19, IBM). A double 
sided P-value < 0.05 was considered significant.
Figure 1. 111In-trastuzumab scintigraphy at first and repeated scintigraphy series during treatment.
111IN-TRASTUZUMAB SCINTIGRAPHY IN HER2 POSITIVE METASTATIC BREAST CANCER PATIENTS 
REMAINS FEASIBLE DURING TRASTUZUMAB TREATMENT
5
111In-trastuzumab scintigraphy at 24, 72, 96, and 168 hours postinjection in the first (A) and repeated (C) scan series. The 





Seventeen patients were included between January 2002 and June 2004. In 12 patients, 
serial analyses of tumor uptake, organ absorbed dose and radiation dosimetry, determined 
from 111In-trastuzumab scintigraphy on first and second scintigraphy series could be 
assessed. In the remaining five patients, three were withdrawn from the study prematurely 
due to clinical deterioration and/or disease progression, and in two patients the scintigraphy 
series were incomplete. 
111In-trastuzumab Tumor Uptake 
In these 12 patients, all in total 25 tumor lesions were detected on 111In-trastuzumab 
scintigraphy at first and repeated scintigraphy series during treatment (See Figure 2 for an 
example). In 20 of the 25 tumor lesions the 111In-trastuzumab uptake was decreased at the 
repeated compared to first scintigraphy series. Mean residence time in tumor lesions was 0.22 
± 0.30 (0.04-1.26) at baseline, and 0.14 ± 0.17 (0.02-0.79) after 12 weekly therapeutic 
trastuzumab doses. Between first and repeated scintigraphy series, there was a mean reduction 
in 111In-trastuzumab uptake per lesion of 19.6% ± 53.8 (range increase of 72.9 to decrease of 
188.5%; P = 0.003). The mean reduction per patient was 17.0% ± 35.0 (P = 0.07). 
111In-trastuzumab Organ Distribution and Radiation Dosimetry
The residence times of healthy organs remained the same between first and repeated 
scintigraphy series, except for an increase in the cardiac blood pool (P = 0.014) (Table 1). 
The absorbed dose for the organs and the effective dose thus also remained similar. The 
effective dose of 111In-trastuzumab was 0.19 ± 0.02 mSv/MBq. The three organs with the 
highest absorbed dose were liver (0.60 ± 0.18 mGy/MBq), spleen (0.36 ± 0.08 mGy/MBq) 
and heart wall (0.34 ± 0.05 mGy/MBq). The three organs with the highest contribution to 
the effective dose were liver (0.030 ± 0.009 mSv/MBq), lungs (0.035 ± 0.007/mSv MBq) 
and ovaries (0.032 ± 0.004 mSv/MBq) (Table 2).
Table 1. Residence times and standard deviations of measured organs. 
Organ Residence time (hours)t = first
Residence time (hours)
t = second/repeated
Blood pool 2.39 ± 0.71 2.78 ± 0.71
Kidney 0.86 ± 0.30 0.86 ± 0.31
Liver 12.96 ± 5.15 11.13 ± 4.29
Lung 3.26 ± 1.09 3.36 ± 1.25
Spleen 0.91 ± 0.33 0.92 ± 0.27
Red marrow 0.78 ± 0.19 0.90 ± 0.22
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Figure 2. 111In-trastuzumab scintigraphy at first and repeated scintigraphy series during treatment.
Table 2. Radiation absorbed dose estimates for organs and effective dose contribution of ICRP 60 
target organs on the first scan series. 
Organ Radiation absorbed dose (μGy/MBq)  ± SD
ICRP 60 Effective dose contribution (μSv/MBq) 
± SD
Adrenal gland 230 ± 17 1.1 ± 0.2
Brain 106 ± 16 0.5 ± 0.1
Breast 115 ± 12 5.7 ± 0.6
Gallbladder wall 277 ± 37 *
Lower colon wall 152 ± 21 18.3 ± 2.6
Small intestine 156 ± 16 0.7 ± 0.1
Stomach wall 181 ± 16 21.8 ± 1.9
Upper colon wall 180 ± 15 0.9 ± 0.2
Heart wall 339 ± 49 *
Kidney 268 ± 42 1.3 ± 0.3
Liver 598 ± 183 29.9 ± 9.1
Lung 291 ± 54 34.9 ± 6.5
Muscle 131 ± 14 0.6 ± 0.1
Ovary 158 ± 21 31.7 ± 4.1
Pancreas 238 ± 17 1.1 ± 0.2
Red marrow 132 ± 15 15.8 ± 1.8
Skin 84 ± 10 0.8 ± 0.1
Spleen 360 ± 78 2.8 ± 3.2
Thymus 167 ± 21 0.8 ± 0.2
Thyroid 117 ± 17 5.8 ± 0.8
Urinary bladder wall 140 ± 20 7.0 ± 1.0
Uterus 156 ± 21 0.7 ± 0.1
Total Body 151 ± 13 *
Effective dose * 185 ± 16
* Not defined
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Discussion and Conclusions
This is the first study with serial 111In-trastuzumab scintigraphy at the start and during 
trastuzumab treatment in patients with HER2 positive metastatic breast cancer. It showed 
persistent 111In-trastuzumab uptake in all tumor lesions during trastuzumab treatment, 
with only a 20% lower absolute uptake after 12 weeks of trastuzumab treatment. This 
indicates that sufficient HER2 is constantly available at the tumor cell membrane to bind 
trastuzumab and that it is impossible to completely saturate the receptor. Furthermore this 
is the first study to present radiation dosimetry data for 111In-trastuzumab. 
There are several potential explanations contributing for the 19.6 % lower 111In-trastuzumab 
uptake during trastuzumab treatment. It may be the consequence of the antitumor effect of 
paclitaxel and trastuzumab on the size of the tumor lesion or on HER2 expression itself. 
Unfortunately, rigorous evaluation of size effects of all tumor lesions was not possible. 
Specific for breast cancer is the fact that most metastases are located in the bones which are 
not included in RECIST. Also no serial biopsies were taken so down regulation of HER2 
expression could not be assessed. Last important explanation for the lower 111In-trastuzumab 
uptake during treatment might be that therapeutic trastuzumab circulating in the blood 
competes with 111In-trastuzumab for binding to HER2. Of the normal organs, only the 
cardiac blood pool showed a 16% higher uptake of 111In-trastuzumab after the second 
injection during treatment. This can be explained by the fact that trastuzumab elimination 
half-life is dose-dependent, after multiple trastuzumab doses half-life time increases16. 
However, we showed that tumor lesions could still be clearly visualized under trastuzumab 
treatment. Thus, we conclude that there is no complete down regulation or saturation of 
the HER2. Preferably this would be confirmed with HER2 staining of tumor tissue in future 
clinical studies. There are however preclinical data available. Preclinical evaluation of 
change of HER2 status on trastuzumab therapy with molecular imaging was performed 
previously in two studies with a human breast cancer xenograft. Micro-SPECT with 111In-
pertuzumab and 18F-FBEM-HER2:243 were performed pre-and post trastuzumab treatment in 
mice bearing human tumor xenografts. Uptake of the tracers was decreased, but not 
completely blocked, after 3 weeks of treatment, which corresponded with changes in 
tumor size17-18. Distinct from our study, there was no competition between the tracer and 
the therapeutic agent in these studies, because both tracers bind to another domain of 
HER2 than trastuzumab. Thus, extrapolating to our study results, we conclude that during 
trastuzumab treatment visualization of tumor lesions with 111In-trastuzumab is feasible and 
not completely blocked or saturated, despite this competition of the (subtherapeutic 
amount of) radiolabelled trastuzumab with therapeutic trastuzumab. 
In a human HER2 overexpressing SKOV-3 ovarian tumor xenograft there was higher 
uptake of 111In-trastuzumab compared to a HER2 negative tumor xenograft11 indicating 
tumor specific uptake. 
CHAPTER 5
75
As no significant differences in organ distribution were found radiation absorbed dose of 
organs between the two scintigraphy series is comparable. Radiation dose estimates with 
111In-trastuzumab were comparable to those calculated by others19. Trastuzumab can also 
be radiolabelled with a positron emission tomography (PET) isotope copper-64 
(NCT01093612) or zirconium-89 (89Zr) for clinical purposes. PET provides a higher spatial 
resolution a better signal to noise ratio and better quantification. No dosimetric results for 
89Zr-trastuzumab have been published so far. However, as the physical half-lives of 111In 
and 89Zr are comparable, the data for 111In-trastuzumab can be used to estimate the ED for 
89Zr-trastuzumab, resulting in an ED of 0.5 mSv/MBq 89Zr. For a typical administration of 
37 MBq of 89Zr-trastuzumab, the radiation dose amounts to 18 mSv, which is comparable 
to the radiation dose of 100 MBq 111In. 
We realize that this study has several shortcomings, mainly because it was originally 
not intended and powered to look at tumor size and HER2 expression over time. However 
while experience with molecular HER2 imaging is expanding, we wondered whether 
trastuzumab treatment affects imaging. The fact that this study showed that all tumor 
lesions remained visible during treatment, means that HER2 imaging is feasible even during 
trastuzumab treatment. 
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Case Report
A 34 year old woman was diagnosed with two right-sided primary breast cancers. One 
tumor was 10 cm in diameter, histological grade 3 and negative for estrogen receptor (ER), 
progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2), while 
the other tumor was 6.5 cm in diameter, grade 3 and ER positive, PgR negative and HER2 
positive. Standard work-up revealed no metastases. Her primary treatment consisted of 
right sided mastectomy with axillary lymph node dissection. This dissection showed tumor 
involvement in 11 out of 14 lymph nodes. Adjuvant treatment consisted of doxorubicin 
and cyclophosphamide followed by trastuzumab combined with paclitaxel. Thereafter 
trastuzumab monotherapy was continued for one year. Chemotherapy was followed by 
tamoxifen and leuprorelin.
Two years since diagnosis, during routine check-up, serum CA15.3 level was elevated 
(70 kU/L). Physical exam was unremarkable. Dissemination analysis showed on computed 
tomography (CT) scan a large mediastinal mass and a small liver lesion, while no lesions 
were present on the bone scan. To determine which primary tumor had metastasized, a 
biopsy of the liver lesion was performed, which showed no tumor cells on histological 
examination. In order to obtain tissue of the mediastinal lesion, a mediastinoscopy would 
be required. Therefore the patient was referred to our hospital, to assess the HER2 status of 
the tumor non-invasively by means of Zirconium-89-trastuzumab (89Zr-trastuzumab) 
positron emitting tomography (PET) imaging. The procedure was carried out as described 
earlier, with acquisition of the PET images 4 days after intravenous administration of 37 
MBq 89Zr-trastuzumab (protein dose 50 mg)1. The PET scan showed uptake in the 
mediastinal mass, lymph nodes in the neck region level 4 on both sides and level 3 right 
sided, and sacral spine (Fig 1). No liver lesions were detected. 
It was concluded from the 89Zr-trastuzumab PET, that the metastatic process was HER2 
positive. Given the progression during hormonal treatment and the large mediastinal mass 
tamoxifen treatment was temporarily discontinued and chemotherapy was initiated. The 
patient received 3 cycles of 5-fluorouracil, epirubicin and cyclophosphamide, followed by 
3 cycles paclitaxel and trastuzumab. Thereafter the CT scan showed a partial tumor 









When metastases of breast cancer are suspected, standard work-up consists of a CT scan of 
the chest and abdomen and a bone scan. In clinical situations in which other staging is 
equivocal or conflicting, an 18F-fluordeoxyglucose PET (FDG-PET) should be considered2,3. 
In addition to this regular work-up for a first tumor recurrence, biopsies are recommended 
to confirm the malignant nature of the lesion, and the presence of ER, PgR and HER2. 
Although clinical guidelines encourage the use of repeated biopsies during the course of 
the disease2,3, in practice, this is not always feasible. Furthermore, sampling error cannot 
be ruled out with repeated biopsies, which is particularly relevant in view of possible 
heterogeneous HER2 expression between the primary tumor and the metastases4, between 
different metastases and within a metastasis. Discordance of HER2 expression between 
primary tumors and metastases, as measured by immunohistochemistry (IHC) and/or 
FISH, varies between 0-33.2%5-16. The largest report included 382 paired primary tumors 
and metastases, which were evaluated by IHC. In this study, a discordant HER2 status was 
found in 33.2% of paired samples: 23.6% changed from positive to negative while 9.6% 
changed from negative to positive16. Between synchronous tumors, there appears to be a 
larger degree of concordance than in metachronous tumors. However, even in synchronous 
tumors a discordant HER2 expression was found in 7 out of 29 patients (24%)17.
Loss or gain of HER2 expression can have clear therapeutic consequences, as patients 
with HER2 positive lesions benefit from anti-HER2 therapy18,19. Therefore it is of interest to 
accurately assess HER2 status during the course of metastatic breast cancer, which is 
possible with a biopsy, but in case of an inaccessible lesion an 89Zr-trastuzumab PET is of 
potential interest.
89Zr-trastuzumab PET was developed, as a noninvasive whole body visualization 
strategy to determine HER2 expression and localization of HER2-overexpressing tumor 
lesions. This includes assessment of the HER2 expression in distant metastases that may 
not be accessible for biopsy and excludes sampling error. Initially, HER2 imaging was 
performed with single photon emission computed tomography (SPECT)-tracer Indium-
111-trastuzumab in HER2-overexpressing metastatic breast cancer. With this technique, 
45% of single tumor lesions, detected with conventional imaging, could be shown. In 
addition, this approach revealed new tumor lesions not previously identified with 
conventional staging in 13 out of 15 patients20. Since PET imaging provides a higher spatial 
resolution and a better signal-to-noise ratio than SPECT, and availability of the long-lived 
positron emitter Zirconium-89 (89Zr) with ideal physical characteristics for immuno-PET, 
allowed to develop the 89Zr-trastuzumab tracer. We showed that PET scanning using 89Zr-
trastuzumab in addition permitted quantification of HER2 positive tumor lesions in breast 
cancer patients1 In a feasibility study, we found that 50 mg 89Zr-trastuzumab, consisting of 
1.5 mg 89Zr-trastuzumab (37 MBq) replenished with nonradioactive trastuzumab, is a dose 
for optimal HER2 visualization in trastuzumab-naive patients. Lower trastuzumab doses 
resulted in rapid excretion by the liver1.
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In the present case, 89Zr-trastuzumab PET was instrumental for non-invasive assessment of 
the HER2 status of metastatic breast cancer. The patient was treated for HER2 positive 
metastatic breast cancer with trastuzumab and paclitaxel, which resulted in a partial 
response. 
The addition of trastuzumab to chemotherapy in HER2 positive metastatic breast 
cancer patients resulted in an increased time to disease progression, higher objective 
response rates, and longer overall survival21,22. Accurate real-time assessment of HER2 
status of metastatic breast cancer can have clear clinical implication for tailored treatment. 
The present case illustrates that 89Zr-trastuzumab PET can be helpful when standard work 
up fails to establish the HER2 status of the metastatic lesions. Therefore, we are currently 
proceeding to assess the role of 89Zr-trastuzumab PET in decision making in a prospective 
multicenter study.
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Abstract
Vascular endothelial growth factor (VEGF)-A is overexpressed in most (pre)malignant 
breast lesions. VEGF-A can be visualized non-invasively with positron emission tomography 
(PET) imaging and using the tracer Zirconium-89 (89Zr) labeled bevacizumab. In this 
clinical feasibility study, we assessed whether VEGF-A in primary breast cancer can be 
visualized by 89Zr-bevacizumab PET. 
Methods: Prior to surgery, breast cancer patients underwent a PET/CT scan of breasts and 
axillary regions, four days after 37 MBq/5 mg 89Zr-bevacizumab intravenous administration. 
PET images were compared with standard imaging modalities. 89Zr-bevacizumab uptake 
was quantified as the maximum standard uptake value (SUVmax). VEGF-A levels in tumor 
and normal breast tissues were assessed with Enzyme-Linked Immuno Sorbent Assay. Data 
are presented as mean ± SD. 
Results: Twenty-five of 26 breast tumors (size: 25.1 mm ± 19.8, range 4-80) in 23 patients 
were visualized. SUVmax was higher in tumors (1.85 ± 1.22, range 0.52-5.64) than in normal 
breasts (0.59 ± 0.37; range, 0.27-1.69; P < .001). The only non-PET-detected tumor was 
10 mm in diameter. Lymph node metastases were present in 10 axillary regions; 4 could be 
detected with PET (SUVmax: 2.66 ± 2.03; range, 1.32-5.68). VEGF-A levels in the 17 
assessable tumors were higher compared to normal breast tissue in all cases (VEGF-A/mg 
protein 184 ± 169 pg v 10 ± 21 pg; P = .001), whereas 89Zr-bevacizumab tumor uptake 
correlated with VEGF-A tumor levels (r = 0.49). 





Breast cancer is the most common cause of cancer related deaths among women1. The 
application of molecular imaging can visualize, and potentially quantifies functional 
differences between tumor and normal cells. A molecular target of interest in this respect is 
vascular endothelial growth factor (VEGF)-A. VEGF-A is involved in the development and 
maintenance of tumorangiogenesis and already involved early during tumorigenesis. 
Various studies have reported overexpression of VEGF-A in breast cancer microenvironment 
compared to normal breast tissue2-5. All VEGF-A splice variants are bound by the clinically 
used monoclonal antibody bevacizumab. When labeled with the PET-isotope zirconium-89 
(89Zr), bevacizumab preserves its VEGF-A binding properties. Thus, tracer dosages of 
radiolabeled bevacizumab can be used for tumor specific, whole body imaging of VEGF-A. 
In preclinical studies6,7 and in a study in renal cell cancer patients8, we have already shown 
an excellent tumor-to-background ratio with an optimum at 4 days after tracer injection 
when using 89Zr-bevacizumab. In the present clinical feasibility study, we used 89Zr-
bevacizumab PET to provide proof-of-principle whether VEGF-A imaging can be used for 
detection of primary breast tumors. 





Eligible patients had a histologically or cytologically confirmed adenocarcinoma of the 
breast and were scheduled for mastectomy or lumpectomy. Additional eligibility criteria 
included a minimum age of 18 years and World Health Organisation (WHO) performance 
status of ≤2. In all patients, standard diagnostics consisted of mammography and 
ultrasonography. When needed to better define tumor extent, MRI was also performed. 
Exclusion criteria included pregnancy or lactation, prior radiotherapy in the involved area, 
major surgery within 28 days before initiation of the study, clinically significant 
cardiovascular disease or prior allergic reactions to immunoglobulins. In premenopausal 
patients, a pregnancy test was performed to exclude pregnancy. 
The study was approved by the Medical Ethics Committee of the University Medical 
Center of Groningen. This local committee was supervised by the Central Committee on 
Research Involving Human Subjects which acts as the competent authority. All patients 
gave written informed consent. The trial is registered under clinicaltrial.gov number 
NCT00991978.
89Zr-bevacizumab PET Imaging
Patients received 37 MBq/5 mg protein 89Zr-bevacizumab as an intravenous bolus injection 
4 days prior to PET scanning and observed for allergic reactions for 1 hour. The dose of 5 
mg bevacizumab was chosen as this was the lowest dose possible which was reproducible 
during the labeling procedure. The same dose was used in a study with indium-111 labeled 
bevacizumab, which visualized all known melanoma lesions9. 89Zr has a decay half-life of 
78,4 hours, the mean beta energy is 395.5 keV, the positron branching fraction is 22.74% 
and the main gamma emissions: 511 keV 45.5% and 909 keV 99.04%. Clinical 89Zr-
bevacizumab was produced as follows: reconstituted bevacizumab (Avastin®, Roche) was 
conjugated with tetrafluorophenol-N-succinyldesferal-Fe (VU University Medical Center, 
Amsterdam, The Netherlands), purificated, and stored at -80°C. Good manufacturing 
practice-produced 89Zr-oxalate (BV Cyclotron, Amsterdam. The Netherlands) was used for 
radiolabeling the conjugate. Quality control was performed to ensure (radio) chemical 
purity (>95%), antigen binding and stability. PET/CT acquisition was performed with a 
Siemens Biograph mCT 64 slice (PET/CT) camera (Siemens, Knoxville, TN). Scanning of 
both breasts and the axillary regions was performed in 2 bed positions with 5 minutes of 
imaging per bed position. In addition a low dose CT scan was performed which was used 
for attenuation and scatter correction. The patient was positioned in prone position with 
hanging breasts. PET data was reconstructed with Siemens iterative reconstruction, 
involving ordinary poison (OP) OSEM 3D reconstruction without time-of-flight and point-
spread-function methods. The settings used for reconstruction were 2 iterations and 8 
subsets, a matrix size of 200 and a post-processing filter of 10 mm, resulting in an effective 
resolution of 11 mm. For sentinel lymph node detection and SPECT imaging as standard 
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of care, 100 MBq Technetium-99m (99mTc) labeled nanocolloid was administered one day 
prior to surgery. To avoid interference of SPECT imaging a minimal interval of 3 half-life 
episodes of 89Zr-bevacizumab (11 days) was taken into account between the administration 
of 89Zr-bevacizumab and 99mTc-nanocolloid to allow for sufficient 89Zr isotope decay. 
89Zr-bevacizumab PET Analysis
Final images analysis was done by a nuclear medicine physician (AHB). Separate analysis 
of the mammography and ultrasonographic images was executed by a radiologist (SBM) 
and compared with the PET images in collaboration with the nuclear medicine physician 
to confirm that the tumor location on both imaging modalities was identical. The uptake 
of 89Zr-bevacizumab in the tumor was quantified using AMIDE Medical Image Data 
Examiner software (version 0.9.3, Stanford University, Stanford, CA)10. For the quantification 
of radioactivity within the tumor, 3D regions of interest (ROIs) were manually drawn 
around the tumor and axillary lymph node metastasis (if present) (SBMG). For determining 
the background also the uptake in the cardiac blood pool, normal breast (ipsi-and 
contralateral) and nipple were quantified. The data is presented as the maximum 
standardized uptake value (SUVmax). Furthermore, the images were analyzed for uptake of 
89Zr-bevacizumab uptake along the cytology or biopsy channel.
Enzyme-Linked Immuno Sorbent Assay (ELISA) to Detect VEGF-A
For quantification of VEGF-A expression in the surgical specimen, an ELISA was performed 
according to the manufacturer instructions (Quantikine®, R&D Systems, Bristol, UK). 
Three random samples were collected from the surgical specimen of the primary tumor, 
ipsilateral normal tissue and nipple tissue. Tissue was lyzed manually using mammalian 
protein extraction reagent (M-PER, Pierce, Rockford, IL). Thereafter, mixtures were 
centrifuged at 20,000 g for 15 minutes and subsequently stored at -20 °C until analysis. 
Results of VEGF-A measurement were normalized for the protein concentration of the 
same samples determined by the Bradford assay11.
Tumor Histology and Immunohistochemistry
Tumor tissue of the surgical specimen was typed and graded according to the WHO and 
modified Bloom en Richardson guidelines, respectively. Immunohistochemistry for VEGF-A 
and Ki-67 was performed on tumors, ductal carcinoma in situ (DCIS) (if present) and 
normal breast tissue using paraffin-embedded slides. Slides were deparaffinized in xylene 
and rehydrated in ethanol. Endogenous peroxidase was blocked by incubation with 0.3% 
hydrogen peroxidase for 30 minutes. Primary antibodies rabbit anti-VEGF-A (A20-c152, 
1:50, Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-Ki-67 (1:300, clone MIB-1, 
DAKO) and mouse anti-CD31 (BD Pharmingen, San Diego CA) were applied for 60 
minutes, followed by suitable secondary antibodies and immunostaining was visualized 
with 3′ 3-diaminobenzidine tetrahydrochloride. Counterstaining was performed with 
hematoxylin. All stainings were scored by two independent observers (SBMG and JB). 
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VEGF-A was scored (negative/positive) at 400× magnification. The proliferation index was 
calculated by counting of Ki-67 positive versus negative cells in at least 5 high power fields 
(400×). Micro vessel density (MVD) was scored in 5 areas defined as hotspots areas with 
maximum number of microvessels.
Breast cancer molecular subtypes according to immunohistochemical profile were 
categorized as follows: luminal A (ER positive or PR positive and Ki-67 < 14%;) luminal B 
(ER positive or PR positive and Ki-67 ≥ 14%), HER2 enriched (ER negative, PR negative, 
and HER2 positive), and basal-like (ER negative, PR negative, HER2 negative). Luminal B 
also included tumors that were ER positive and/or PR positive and HER2 positive12.
Phantom Study
In order to define the detection limit of the PET/CT camera system, a breast simulation 
phantom study was carried out. Breast-shaped phantoms were produced as described 
earlier13,14. For tumor-like agarose inclusions, 2% agarose (Hispanagar, Burgos, Spain) was 
suspended in tris-buffered saline and heated to 70 °C. Subsequently, 89Zr-oxalate was 
dissolved to a final concentration of 7,700 Bq/mL. Silicone molds were filled with the 
agarose mixture to create tumor-like inclusions ranging from 5 to 20 mm in diameter.
Breast phantoms were constructed with two tumor-like inclusions. PET imaging was 
performed on day 1 and every 3 to 4 days until visual disappearance of the lesions on the 
scan. Final image analysis was performed as stated above. The recovery coefficient was 
determined by calculating the ratio between the measured amount of 89Zr on the PET and 
the inserted dose measured by a dose calibrator, corrected for decay.
Statistical Analyses
Data are presented as a mean ± standard deviation (SD). Statistical analysis was performed 
using the paired t-test test or Wilcoxon signed rank test for paired data and the unpaired 
t-test for unpaired data. Associations between parameters were evaluated using Pearson’s 






A total of 23 patients with 26 breast tumors were included. Patients had no history of prior 
malignancies. Two women had bilateral breast cancer and one patient had two ipsilateral 
tumors. Patient and tumor characteristics are shown in Table 1. Breast tumors were detected 
with mammography (n = 22), ultrasound (n = 25) or MRI (n = 1). Histological analyses 
showed invasive ductal carcinoma (n = 23), invasive lobular carcinoma (n = 2) and invasive 
tubular carcinoma (n = 1). Of the 25 available invasive cancers, 9 tumors were classified as 
luminal A and 14 as luminal B breast cancer. There was one basal like- and one HER2 
enriched tumor. Six patients had pathologically proven axillary lymph node metastases 
prior to surgery. In three additional patients, tumor cells were detected in the sentinel 
lymph node after surgery. In a patient with bilateral breast cancer, axillary lymph node 
involvement on one side was already known prior to surgery and was also detected in a 
sentinel lymph node of the opposite axilla. 
Table 1. Patient-and tumor characteristics
Patients (n = 23)
Tumors (n) 26
Median age patient, years (range) 54.9 ± 10.2 (32-73)
Tumor size mm (range) 25.1 ± 19.8 (4-80)
Tumor type (n)
- Invasive ductal carcinoma 23
- Invasive lobular carcinoma 2
- Invasive tubular carcinoma 1



































Analysis per patient (X-axis). 
The ratio between 89Zr-
bevacizumab uptake expressed 
as SUVmax in breast tumors 




Axial slices of 89Zr-bevacizumab PET from a patient with a primary breast tumor (1) and lymph node metastasis (2). 
89Zr-bevacizumab PET
In this study, no adverse events were seen. 89Zr-bevacizumab PET imaging showed uptake 
in 25 of the 26 breast tumors (96.1%). Figure 1 shows a representative example. Uptake of 
89Zr-bevacizumab was higher in breast tumors than in normal breast tissue (of both the 
ipsi- and contralateral breast); SUVmax in breast tumors was 1.85 ± 1.22 (range, 0.52-5.64) 
v 0.59 ± 0.37 (range, 0.27-1.69) in ipsilateral normal breast tissue and 0.51 ± 0.26 (range, 
0.20-1.12) in contralateral normal breast tissue; (both P < .001) (Figure 2A). There was a 
similar 89Zr-bevacizumab uptake in normal tissue of both breasts (P = .88). SUVmax of 
luminal A tumors was 1.28 ± 0.58 compared to 2.04 ± 1.08 in luminal B tumors (P = .06). 
In the patients with a basal like and HER2 overexpressing breast tumor, SUVmax was 0.52 
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and 5.64, respectively. The only breast tumor which did not show preferential 89Zr-
bevacizumab uptake was an invasive ductal carcinoma with a diameter of 10 mm. Lymph 
node metastases (size ranging 3-42 mm), were present in 10 axillary regions (of 9 patients); 
4 of these lymph node positive axillary regions were detected by PET (SUVmax 2.66 ± 2.03, 
range 1.32 - 5.68). All four positive axillary regions were already known prior to surgery 
based on ultrasound and cytology. 89Zr-bevacizumab PET detected none of 4 positive 
axillary regions with 1-3 lymph node metastases (pN1), and 4 out of 6 positive axillary 
regions with 4 or more lymph node metastases (≥ pN2). There were no false positive 
readings and there was no 89Zr-bevacizumab uptake along the cytology or biopsy tract.
Next to tumor visualization there was slightly higher uptake in the nipples of both 
breasts compared to background in 20 of the 23 patients. SUVmax of nipple tissue was 1.13 
± 0.59 (range 0.47 - 3.02). This is lower than the SUVmax in tumor tissue (P = .01). SUVmax 
in the blood pool on day 4 was 4.17 ± 1.07 (range 2.97 - 7.05), which is 2.3 and 3.7 fold 
higher than in the tumors and nipples respectively. 
VEGF-A ELISA 
For VEGF-A ELISA measurements, surgical specimens of 17 breast tumors and 24 
specimens of normal ipsilateral breast tissue were available. Pathologic examination of the 
tissue confirmed tumor in all macroscopic tumors. Mean tumor VEGF-A/mg protein was 
higher (184 pg ± 169) than in normal breast tissue (10 pg ± 21, P = .001) (Figure 2). In the 
tumor of 10 mm which was not detected by 89Zr-bevacizumab PET, 371 pg/mg protein 
VEGF-A was measured. 89Zr-bevacizumab tumor uptake of the 89Zr-bevacizumab detected 
tumors correlated with the VEGF-A protein level (Pearson r = 0.49, P = .04) (Figure 3). 
In the 11 available nipple specimens (from one patient with bilateral breast cancer both 
nipples) VEGF-A level was 10 pg ± 13 per mg protein, which was not different from normal 
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Correlation between 89Zr-bevacizumab tumor 
uptake (X-axis) and tumor VEGF-A (Y-axis) 




All available tumors (n = 25) showed positive staining for VEGF-A expression. VEGF-A 
expression in normal tissue was absent in two and present in 23 of the 25 operated breasts. 
DCIS was present in 10 patients and stained positive for VEGF-A in all cases. 89Zr-
bevacizumab tumor uptake correlated positively with a mean proliferation index of 32.1 ± 
24.3 (range 6.0-86.0) (Pearson r = 0.55, P = .005) (Figure 4). The MVD was not correlated 
with 89Zr-bevacizumab uptake (r = 0.10, P = 0.64).
Phantom Study 
All tumor-like inclusions were visible on day 1. The recovery coefficient was 73% for the 
smallest inclusion and 96% for the largest one. The last time point before visual 
disappearance was day 1 (5 mm inclusion), day 10 (10 mm inclusion), day 14 (15 mm 






























Correlation between 89Zr-bevacizumab tumor uptake 
(X-axis) and proliferation index (Y-axis) as measured 




This is the first clinical feasibility study with 89Zr-bevacizumab PET in breast cancer 
patients. Uptake of 89Zr-bevacizumab was visualized in 96.1% of the primary tumor lesions 
and there was a relation with the level of VEGF-A in the tumor. This provides proof that 
89Zr-bevacizumab might be potentially valuable for biological characterization of tumors as 
well as prediction and evaluation of the effect of VEGF-A targeting therapeutics.
VEGF-A is reported in several studies to be overexpressed in malignant breast tumors 
as well as in DCIS5,15, thus covering the full spectrum of early stage breast cancer to more 
advanced stages. More frequent VEGF-A staining was found to be related to aggressiveness 
as assessed by VEGF-A staining in a study with 1,788 breast tumors5. 89Zr-bevacizumab 
PET proved to be able to detect a broad range of VEGF-A expression levels. Quantitative 
tumor analyses showed a more than 10-fold difference between individual SUVmax 
suggesting large differences in VEGF-A tumor levels between patients, which was confirmed 
by the broad difference in VEGF-A measured by ELISA. Although there was a high 
visualization rate, the SUVmax of tumors and normal tissues do overlap in this study. 
Importantly in individual patients, SUVmax was always higher in tumor than in normal 
breast tissues. The higher VEGF-A ratio between tumor and normal breast measured by 
ELISA compared to PET, might be explained by the fact that (in contrast to 89Zr-bevacizumab 
PET) the ELISA also measures intracellular VEGF-A16. Moreover, the resolution of the PET 
camera is 10 mm while ELISA and immunohistochemistry measure on cellular level. 
89Zr-bevacizumab uptake in the primary breast tumors was relatively low, compared to 
uptake in a series of 22 metastatic renal cell cancers in our institution (mean SUVmax 1.85 
v 10.1)15. Anti-angiogenic treatment has monotherapy activity in renal cell cancers which 
is not the case in tumor types such as breast cancer17,18. The difference in 89Zr-bevacizumab 
uptake, and therefore VEGF-A levels, is possibly related to this varying efficacy. 89Zr-
bevacizumab might be potentially valuable for biological characterization of tumors as well 
as prediction and evaluation of the effect of VEGF-A targeting therapeutics.
The failure to detect one tumor lesion with the size of 10 mm in diameter out of 26 lesions, 
despite sufficient VEGF-A expression, can be explained by the findings in our phantom 
study. Small lesions visually disappear much earlier on 89Zr-PET compared to larger lesions. 
This effect might influence the tumor uptake of 89Zr-bevacizumab measured by SUVmax. 
The observed effect of tumor size on PET detection is shared by FDG-PET19,20, but is larger 
in case of 89Zr-PET. Due to the higher radiation dose per MBq of 89Zr, a lower amount of 
activity was injected compared to FDG. 89Zr has a smaller yield of positron compared to 18F 
which results in increased noise and therefore 89Zr-bevacizumab PET images require more 
smoothing. This degrades resolution and increases size effects. Importantly, imaging with 
89Zr-bevacizumab PET delivered no false-positive lesions.
Most patients had uptake of 89Zr-bevacizumab in the region of the nipple, while the 
VEGF-A level as measured with ELISA was low and equal to normal tissue. 89Zr has a long 
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half life of 78.4 h. When labeled to bevacizumab, a considerably amount of the tracer 
remains in the circulation. Therefore, the uptake of 89Zr-bevacizumab in the nipple is likely 
due to high vascularization of the nipple compared to normal breast tissue21. In the tumor, 
the contribution of perfusion to increased 89Zr-bevacizumab uptake in the tumor is less 
likely to play a role, based on preclinical and clinical data. In a xenograft mouse model, we 
have shown that tumor accumulation of 89Zr-bevacizumab increases in time, while uptake 
in normal organs decreases6. This increase in 89Zr-bevacizumab tumor accumulation over 
time was also shown in melanoma patients who underwent 111In-bevacizumab SPECT9. In 
a human SKOV-3 ovarian tumor xenograft there was higher uptake of 89Zr-bevacizumab 
compared to 89Zr-IgG6 indicating tumor specific uptake. 89Zr-IgG PET in the patient setting 
is not possible due to radiation exposure concerns. This is also the limiting factor in using 
89Zr-bevacizumab PET in healthy subjects as a negative control. However, the MVD did not 
influenced 89Zr-bevacizumab uptake. Moreover, the relation between VEGF-A measured by 
ELISA and 89Zr-bevacizumab uptake in tumors and not in nipple tissue, is in line with the 
preclinical findings that the tracer uptake is in fact tumor specific.
The limiting factor for more general application of imaging with radionuclides is the 
radiation burden. In a study comparing the risks of radiation-induced cancer from 
mammography, molecular breast imaging (MBI) and positron emitting mammography 
(PEM), the cumulative cancer incidence is 15-30 times higher for PEM and MBI compared 
to mammography22. The estimated radiation burden of 89Zr-bevacizumab-PET is 19 
milliSieverts (mSv) per tracer injection, based on extrapolation from 111In-bevacizumab 
data and a dosimetry study on 89Zr-U36, compared to 5.3 mSv for FDG-PET23-25. 
 
To make optimal use of the tumor specificity of molecular imaging of VEGF-A while 
overcoming radiation issues, bevacizumab was also linked to the near-infrared fluorescent 
dye IRDye 800CW in our institution. This technique has already been tested in human 
xenograft-bearing athymic mice, detecting tumor lesions in vivo with high sensitivity and 
specificity. IRdye 800CW labeled bevacizumab revealed submilimeter lesions with a clinical 
intraoperative fluorescence camera26. Recently, we started a study with IRDye 800CW 
labeled bevacizumab in early breast cancer (NCT01508572). The aim of this study is to 
determine the uptake of the VEGF-A targeting fluorescent tracer in breast tumors, both 
during preoperative diffuse optical tomography as well as during surgery. This approach 





In this first clinical feasibility study with 89Zr-bevacizumab PET in breast cancer patients, 
we have shown that uptake of 89Zr-bevacizumab was visible in most primary breast tumors 
and correlated with the protein level of VEGF-A in the tumor. These findings support use 
of VEGF-A imaging in breast cancer for future imaging purposes. 
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Translational relevance
Metastatic breast cancer is rarely cured and finding treatment for this disease is an unmet 
clinical need. Heat shock protein 90 (HSP90) is a target of interest in cancer treatment, as 
a molecular chaperone which plays a critical role in protein folding and thereby functioning 
of a broad range of cancer related client proteins. Gaining insight of in vivo degradation of 
client proteins caused by HSP90 inhibition is challenging. In this clinical trial, the effect of 
HSP90 inhibitor NVP-AUY922 on client proteins human epidermal receptor 2 (HER2) or 
vascular endothelial growth factor (VEGF; with hypoxia inducible transcription factor 
(HIF)-1α as the actual client protein) was studied with 89Zr-trastuzumab PET or 89Zr-
bevacizumab PET, in patients with advanced HER2 or estrogen receptor (ER) positive 
metastatic breast cancer. The results of PET imaging were correlated with conventional CT 
scanning. 89Zr-trastuzumab uptake on PET at 3 weeks correlated with CT responses in 
individual lesions at 8 weeks and revealed areas of heterogeneous response in patients with 
HER2 amplified metastatic breast cancer. Thus novel PET probes such as 89Zr-trastuzumab 
can be used to provide insights into responses to novel agents active in HER2 amplified 




Purpose: Heat shock protein 90 (HSP90) chaperones have key client proteins that are 
involved in all hallmarks of breast cancer growth and progression. The primary aim of this 
clinical trial was to evaluate the feasibility of using 89Zr-trastuzumab PET (for human 
epidermal receptor 2 (HER2) positive breast cancer) or 89Zr-bevacizumab PET (for estrogen 
receptor (ER) positive breast cancer) to determine in vivo degradation of client proteins 
caused by the novel HSP90 inhibitor NVP-AUY922. 
Experimental design: 70 mg/m2 NVP-AUY922 was administered intravenously in a 
weekly schedule to patients with advanced HER2 or ER positive breast cancer. Biomarker 
analysis consisted of serial PET imaging with 18F-fluordeoxyglucose (FDG), 89Zr-
trastuzumab or 89Zr-bevacizumab. Response evaluation was performed according to 
RECIST1.0. FDG, 89Zr-trastuzumab and 89Zr-bevacizumab distribution were scored visually 
and quantitatively by calculating the maximum standardized uptake values (SUVmax). In 
blood samples, serial HSP70 levels, extracellular form of HER2 (HER2-ECD) and 
pharmacokinetic and pharmacodynamic parameters were measured. 
Results: Sixteen patients (10 HER2 positive, 6 ER positive tumors), were included. One 
partial response was observed; 7 patients showed stable disease. SUVmax change in individual 
tumor lesions on baseline versus 3 week 89Zr-trastuzumab PET was heterogeneous and 
related to size change on CT after 8 weeks treatment (r2 = 0.69; P = 0.006). Tumor response 
on 89Zr-bevacizumab PET and FDG-PET was not correlated with CT response. Conclusions: 
NVP-AUY922 showed proof of concept clinical response in HER2 amplified metastatic 
breast cancer. Early change on 89Zr-trastuzumab PET was positively associated with change 
in size of individual lesions assessed by CT. 
89ZR-TRASTUZUMAB AND 89ZR-BEVACIZUMAB PET TO EVALUATE THE EFFECT 




Metastatic breast cancer remains an incurable disease in the majority of cases, despite 
advances in systemic treatment that have improved median survival1,2. The development of 
novel agents for this disease is an area of unmet need. Heat shock protein 90 (HSP90) is a 
molecular chaperone which plays a critical role in protein folding and function of a broad 
range of client proteins3. HSP90 client proteins playing a role in metastatic breast cancer 
include human epidermal growth factor receptor 2 (HER2), the hypoxia inducible 
transcription factor (HIF)-1α and the estrogen receptor (ER)4-6. HER2 is a sensitive client 
protein of HSP90, which can be depleted by HSP90 inhibition with NVP-AUY922 in many 
different preclinical experiments including breast cancer models7,8. HIF-1α is the key factor 
involved in upregulating the transcription of vascular endothelial growth factor (VEGF)-A 
in hypoxic cells9. HSP90 is overexpressed in metastatic breast cancer. In addition, HSP90 
in tumor cells preferentially binds to HSP90 inhibitors compared to normal cells, which 
further validates HSP90 as a cancer target10,11. Thus there are many different reasons for 
evaluating HSP90 inhibitors in breast cancer. Several HSP90 inhibitors are currently in 
clinical development. Of the resorcinyclic pyrazole/isoaxazole amide analogues, HSP90 
inhibitor NVP-AUY922 is the most potent8. NVP-AUY922 is active against HER2 positive 
as well as HER2 negative human breast cancer cells in vitro and in vivo8,12,13. Clinical 
responses to HSP90 inhibitors have been shown in multiple early phase studies14-16. 
Furthermore, HSP90 inhibition has shown efficacy when used in conjunction with other 
HER2 targeting agents such as trastuzumab17. Nonetheless, gaining insight into the in vivo 
degradation of client proteins caused by HSP90 inhibition is challenging.
In this setting, in vivo visualization of HSP90 inhibition effect might be helpful. 
18F-fluordeoxyglucose (FDG)-positron emission tomography (PET) for assessing tumor 
glucose metabolism, is used to monitor early drug response to anticancer agents18-21. More 
target based imaging of HSP90 inhibition effect was performed in preclinical studies, in 
which critical client proteins VEGF and HER2 could be visualized with zirconium-89 
(89Zr)-bevacizumab PET, gallium-68-(Fab’2)trastuzumab PET and 89Zr-trastuzumab PET 
imaging22-24. In human breast cancer xenograft mouse model models, tumor uptake of 
18F-FDG was unaffected by treatment with the HSP90 inhibitor 17AAG, while radiolabeled 
trastuzumab tumor uptake was on average reduced by 50%. This indicates that target 
based imaging may be more useful as an early biomarker for HSP90 inhibition than 
metabolic 18F-FDG imaging24. 89Zr-trastuzumab PET and 89Zr-bevacizumab PET has been 
used in several clinical trials, including in breast cancer specific studies25-27. 
To evaluate HSP90 inhibition effect on the in vivo degradation of client proteins, blood-
based assays have been used. Serial circulating HER2 extracellular domain (HER2-ECD) 
measurements predicted response to trastuzumab-based therapy in a study of 55 patients28. 
In a phase 1 study with NVP-AUY922, plasma NVP-AUY922 levels and pharmacodynamic 
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biomarkers such as HSP70 induction in peripheral blood mononuclear cells (PBMC) were 
assessed, in addition to establishment of the toxicity profile29. 
Thus, the primary aim of this clinical trial with HSP90 inhibitor NVP-AUY922 in HER2 or 
ER positive metastatic breast cancer patients, was to evaluate the feasibility of using serial 
FDG-PET and novel 89Zr-trastuzumab PET or 89Zr-bevacizumab PET to determine the in 
vivo degradation of client proteins caused by the HSP90 inhibitor NVP-AUY922. 
Furthermore, we aimed to evaluate whether these assessments were related to CT response 
(according to RECIST) and serum shed HER2 levels (if applicable), and to underpin these 
assessments with evidence of pharmacokinetic and pharmacodynamic parameters which 
have already been defined in detail in the previous phase I study29.
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Eligible patients for treatment with NVP-AUY922, had a diagnosis of histologically 
confirmed, measurable progressive metastatic or locally advanced breast cancer, and had 
received up to two prior lines of cytotoxic therapy for advanced disease. In addition, 
patients with HER2 positive breast cancer were required to have a history of trastuzumab 
resistance and up to a maximum of 3 anti-HER2 based regimens for advanced disease. 
Patients with ER positive breast cancer had progressive disease on at least one and up to a 
maximum of three lines of standard endocrine therapy. Further eligibility criteria included: 
age ≥ 18 years, World Health Organisation (WHO) performance status ≤ 2, at least one 
measurable lesion evaluable with RECIST1.030, HER2 positive ((immunohistochemistry 
(IHC) 3+ or fluorescent in situ hybridization (FISH) ratio ≥2, or ER positive breast cancer 
(archival primary tumor tissue), and resolution of toxicities from other therapies to National 
Cancer Institute common terminology criteria for adverse events (NCI CTCAE version 3.0) 
grade ≤ 2. Patients should have adequate hematological, hepatic and renal function which 
was defined by laboratory values, adequate cardiac function defined by electrocardiogram 
(ECG) and MUGA scan or ultrasound. Patients eligible for treatment with NVP-AUY922 in 
this trial (Trial Registration ID: NCT00526045), were also eligible for assessment of 
treatment effect with 89Zr-trastuzumab PET (Trial Registration ID: NCT01081600) for 
HER2 positive breast cancer or 89Zr-bevacizumab PET (Trial Registration ID: NCT01081613) 
for ER positive breast cancer. 
This clinical trial was performed at the University Medical Center of Groningen 
(Groningen, The Netherlands) and the Royal Marsden Hospital (London, United Kingdom). 
Medical ethical committee approval was obtained in both institutions. All patients signed 
written informed consent. Consent for the 89Zr-trastuzumab PET or 89Zr-bevacizumab side 
studies was obtained separately from consent for the clinical trial with NVP-AUY922 
treatment.
Treatment
NVP-AUY922 was administered once a week intravenously at a starting dose of 70 mg/m2 
which was the recommended phase II dose in the first-in-human phase I trial with 
monotherapy NVP-AUY92229. As per protocol doses were reduced to 54 mg/m2 for 
significant adverse events which were defined as ≥ grade 3 toxicity or grade 2 toxicity for 
at least 7 days. NVP-AUY922 was discontinued for any grade 4 toxicity.
Toxicity Assessments 
Patients were examined and assessed for adverse events weekly, and toxic effects were 
graded with the NCI CTCAE version 3.0. A complete blood and platelet count and serum 
chemistry panel measurement were repeated every week in the first 2 cycles, thereafter 
once every 2 weeks. After reports of visual symptoms in the phase I study, this trial required 
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complete ophthalmologic assessment including testing for visual acuity, intraocular 
pressure, slit-lamp, dilated fundus and color-vision. Additional an electro retinogram was 
conducted. All opthalmologic examinations were performed at baseline, when visual 
symptoms became present and at the end of cycle 2. 12-lead electrocardiograms were 
obtained at baseline and before and after every NVP-AUY922 infusion. The 
electrocardiograms were assessed for changes in QT duration. Patients were instructed to 
use loperamide as needed for diarrhea.
89Zr-trastuzumab and 89Zr-bevacizumab PET imaging
Patients with HER2 positive breast cancer, who consented to the 89Zr-trastuzumab PET 
imaging side study, received 37 MBq/50 mg 89Zr-trastuzumab intravenously. Production of 
clinical grade 89Zr-trastuzumab as described previously31. Each patient underwent a PET 
scan on day 2 and 4 postinjection. Two scan sequences were performed, with 89Zr-
trastuzumab injections at baseline and at day 15 of cycle 1. For patients with ER positive 
breast cancer, who consented to the 89Zr-bevacizumab PET imaging side study, a similar 
time frame was used after injection of 37 MBq/ 5 mg 89Zr-bevacizumab. Clinical grade 89Zr-
bevacizumab was produced as described earlier26. 89Zr-trastuzumab and 89Zr-bevacizumab 
distribution were scored visually and quantitatively by calculating the mean and maximum 
standardized uptake values (SUVmean/max) at baseline and following NVP-AUY922 treatment 
(SBG, AHB). If > 10 tumor lesions were visualized in one organ, then 10 were quantified. 
A high correlation was found between SUVmean and SUVmax for healthy organs and tumor 
lesions (Pearson r2 = 0.99 and r2 = 0.97 respectively, P < 0.0001). Since it is less operator 
dependent, we present data as SUVmax. Response on 
89Zr-trastuzumab and 89Zr-bevacizumab 
PET was compared with the response on CT after 8 weeks, only lesions of at least 1.0 cm 
were used to compare.
Pharmacodynamic markers 
HSP70 and HER2-ECD were quantified by enzyme linked immunosorbent assays (ELISA) 
in PBMC and serum samples, respectively. PBMC samples were collected pre-treatment and 
5, 24 and 48 hours post dose and prior to infusion on day 8. Serum samples were collected 
at baseline, pre-treatment at cycle 1 and 2 day 1, day 3, day 8, day 15 and every odd cycle. 
Assessment of tumor response by CT and FDG-PET
Imaging included a CT-scan of the chest, abdomen and pelvis, performed pre-treatment 
and at the end of every even cycle. CT-scans were assessed for tumor response by two 
independent radiologists according to RECIST1.0 criteria30. All patients with a partial 
response (PR) or complete response (CR) were required to have confirmation of response 
performed ≥ 4 weeks after the criteria for response were first met. In case of stable disease 
(SD), follow-up measurements must have met SD criteria at least once after study entry at 
a minimum interval of 6 weeks. The best overall response was defined as the best response 
recorded from the start of the treatment until disease progression or withdrawal from the 
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study. Clinical benefit rate was defined as CR+PR+SD. In a waterfall plot, best change in 
longitudinal tumor size will be presented. Whole body FDG-PET scans were performed at 
baseline and after 4 and 8 weeks. The acquisition protocol was standardized across sites. 
Patient needed to fast for approximately 6 hours prior to FDG-PET scanning. The patient 
was encouraged to maintain good hydration. Glucose levels were measured prior to the 
administration of FDG. The patient needed a blood glucose value of ≤200 mg/dL in order 
for the patient to have the FDG-PET. These scans were assessed per center by two 
independent nuclear medicine specialists blinded for clinical information. FDG-PET scans 
were assessed for new tumor lesions. In addition, up to five lesions with the highest uptake 
were identified on the baseline scans as index lesions. The index lesions were scored 
quantitatively by calculating the maximal standardized uptake value (SUVmax). The 
percentage of change was subsequently calculated. The definitions for metabolic response 
were defined according to the EORTC, into a group with CR or PR (< −25%), a group with 
SD (−25% to +25%), and a group with PD (> +25% and/or new tumor lesions)32.. Response 
on FDG-PET was compared with the response on CT after 8 weeks, only lesions in the field 
of view of the CT and a size of at least 1.0 cm were used to compare.
Drug concentration measurements and pharmacokinetic (PK) assessment
Blood sampling to characterize PK was performed on cycle 1 day 1, immediately prior to 
NVP-AUY922 infusion, 5 minutes, 15 minutes, 30 minutes during NVP-AUY922 infusion, 
immediately prior to the end of the infusion, at 5 minutes, 30 minutes, 1, 2, 4, 5, 8, 24, 48 
and 72 hours post infusion and prior to infusion on day 8. The sample was centrifuged at 
a minimum of 1500 g for 15 minutes and all plasma was transferred in tubes. An additional 
2 mL of whole blood was obtained for plasma assay of NVP-AUY922 and its pharmacologically 
inactive metabolite BJP762 at the following time points: on cycle 1 day 1 at the end of the 
infusion, and then 1, 5 and 24 hours post infusion. Due to the light sensitivity of NVP-
AUY922 and its lack of stability in handling, all blood samples were protected from light 
during collection, handling, and processing and then stored at -70°C. 
The blood and plasma samples collected were assayed for NVP-AUY922 and BJP762 
concentrations by Novartis using a validated liquid chromatography-tandem mass 
spectrometry assay (LC-MS/MS). Values below the lower limit of quantification of 0.8 ng/
mL were reported as 0.00 ng/mL. PK parameters were determined by non-compartimental 
method using WinNonlin Pro (Version 5.2).
Statistical analysis
All clinical data were collected by electronic data capture (Timaeus). Data are presented as 
mean ± standard deviation and range. Statistical analysis was performed using a paired 
sampled T-test for paired data. For correlation of the companion biomarker with RECIST 
1.0 the Pearson’s test was used. The Kaplan-Meier method was used to estimate rates of 
progression over time and median times to progression (SPSS, version 19). All testing was 





Sixteen patients were enrolled between February 2010 and July 2011. Baseline 
characteristics are summarized in Table 1. All patients have discontinued treatment (range 
1-11 months), 13 (81%) because of radiological disease progression and two patients 
because of clinical progression (13%). One patient (6%) stopped treatment because of 
grade 2 nausea which did not resolve after dose reduction. 
Table 1. Patient characteristics at study entry.
Patients with HER2 
positive BC
n = 10 (%)
Patients with ER 
positive BC
n = 6 (%)
All patients
n = 16 (%)














Body surface area-m2 (SD) 1.9 (0.3) 1.8 (0.3) 1.8 (0.3)












































*Left ventricular ejection fraction
Toxicity
The actual cumulative administered doses of NVP-AUY922 were lower than planned: 
951.2 mg/m2 versus 1175.4 mg/m2. Eight patients required a dose reduction to 54 mg/m2. 
Median time to reduction was 2.5 weeks (range 2-6). The most frequent adverse events (all 
grades, regardless of causality) were summarized in Table S1. Nine serious adverse events 
occurred in 6 (37.5%) of the patients, none of which were suspected to be related to study 
drug. Scan procedures were uneventful, except in one case, in which the patient developed 
89ZR-TRASTUZUMAB AND 89ZR-BEVACIZUMAB PET TO EVALUATE THE EFFECT 
OF THE HEAT SHOCK PROTEIN 90 INHIBITOR NVP-AUY922 IN METASTATIC BREAST CANCER PATIENTS
7
112
shivering, rigors, and bronchospasm after 89Zr-trastuzumab administration. This was 
completely reversed within 10 minutes by hydrocortisone and chlorpheniramine 
administration, in line with a mild allergic reaction to trastuzumab. No more scan 
procedures with 89Zr-trastuzumab were performed in this patient.
PET imaging 
Repeated FDG-PET could be performed in 8 of 10 patients with HER2 positive breast 
cancer, and in all of 6 patients with ER positive breast cancer. Best percentage change from 
baseline for FDG-PET SUVmax is shown graphically in Figure 1. Partial metabolic response 
was seen in 5 patients, four with HER2 positive breast cancer and 1 with ER positive breast 
cancer. Mean decrease in SUVmax on FDG-PET after 4 and 8 weeks, was 12% ± 22% and 7% 
± 30% respectively (P = 0.09). Response on FDG-PET was not correlated with response on 
CT after 8 weeks (r2 = 0.18; P = 0.12 at 4 weeks and r2 = 0.17; P = 0.13 at 8 weeks). 
Figure 1.
Maximal percentage change in SUVmax of target lesions on FDG-PET between baseline and after 3 weeks of treatment, in 
patients with HER2 positive (A) and ER positive (B) breast cancer. Repeated FDG-PET could be performed in 8 of 10 patients 
with HER2 positive breast cancer, and in all of 6 patients with ER positive breast cancer.
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Repeated 89Zr-trastuzumab PET could be performed in 5 patients with HER2 positive 
disease, one patient only received the baseline scan. Twenty-nine lesions were visible on 
89Zr-trastuzmab PET. Visual analysis of PET imaging showed a time dependent accumulation 
of 89Zr-trastuzumab within the tumors at day 2 and 4 after 89Zr-trastuzumab injection. The 
following analyses therefore reflect day 4 data from 89Zr-trastuzumab PET at baseline and 
during treatment (the latter is now referred to as 3 week scan). Figure 2 shows a 
representative 89Zr-trastuzumab PET. The mean SUVmax of 
89Zr-trastuzumab uptake at 
baseline was 9.0 ± 7.6 (0.9-26.9), decreasing during treatment to 7.8 ± 6.3 (range 0.7-
24.2, P = 0.047). Heterogeneous treatment effect on SUVmax in the 29 individual tumor 
lesions was observed, both within and between patients (Figure 2; Table S3). There was a 
correlation between the mean decrease in SUV on 89Zr-trastuzumab PET scans after 3 
weeks compared to baseline, and the change of size of tumor lesions on CT after 8 weeks 
of treatment compared to baseline (r2 = 0.69, P = 0.006) (Figure 3). 
Figure 2.
Representative coronal 89Zr-trastuzuzmab PET images of a patient scanned before (A) and after (B) 3 weeks of treatment. 
Multiple liver lesions and one splenic lesion are shown. 89Zr-trastuzumab PET could be performed in 6 of 10 HER2 positive 
patients of which 5 underwent repeated scan procedures. The CT-scan pre-treatment is shown in panel C. Panel D shows a 
heterogeneous response in individual tumor lesions (n = 29) between baseline and follow-up, with an average decrease in 
SUVmax of 18%.
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Of patients with ER positive breast cancer, 5 underwent a repeated 89Zr-bevacizumab PET 
scan, one patient only received the baseline scan. Visual analysis of PET imaging at day 2 
and 4 post tracer injection showed a time dependent accumulation of 89Zr-bevacizumab 
within the tumor lesions, with on day 4 a 1.12 fold higher 89Zr-bevacizumab tumor uptake 
compared to day 2. The following analyses therefore reflect day 4 data from 89Zr-
bevacizumab PET at baseline and during treatment. Figure 4 shows a representative 89Zr-
bevacizumab-PET. SUVmax on the day 4 scan at baseline was 2.3 ± 1.1 (range 0.9-5.2) 
which was unaffected during treatment with 2.4 ± 1.4 (range 0.6-6.6) (P = 0.56). Because 
of a high physiologic liver uptake of 89Zr-bevacizumab, liver lesions could not be visualized, 
except for two patients in whom the liver metastases were not accumulating 89Zr-
bevacizumab, therefore leaving a ‘cold’ spot that could be visualized. Twenty-three lesions 
at baseline were detected in five patients, 20 of them were bone lesions which were also 
detected on FDG-PET, but not measurable on CT (Table S4). 
Panel A shows correlation of 
percentage change in SUVmax of 
89Zr-
trastuzumab (x-axis) per lesion (n = 9) 
between baseline 89Zr-trastuzumab-
PET of 5 patients and after 3 weeks 
NVP-AUY922 treatment, and change 
in size of corresponding lesions on 
CT (y-axis) between baseline and 
after 8 weeks treatment with NVP-
AUY922 (y-axis) (r2 = 0.69, P = 
0.0057). Panel B shows correlation 
of maximal increase of HER2-ECD (n 
= 6) compared to baseline (x-axis), 
and change in size of CT in all target 
lesions of an individual patient 





At baseline, measurement of HSP70 levels in PMBCs was performed in 15 patients. Median 
HSP70 levels were 29.0 ng/mg (range 10.0-69.1). Between baseline and follow up 
measurements, the medium of all maximal HSP70 increases in PBMCs in these patients was 
359.4% ± 350.5. The induction in HSP70 confirmed target inhibition defined in a previous 
phase 1 study29. A higher baseline level of HER2-ECD was correlated with a larger tumor 
size decrease on CT, (Pearson r2 = 0.60; P = 0.025). The median of maximal HER2-ECD 
increase was 13.6% ± 33.4%, which was also positively correlated with tumor size decrease 
after 8 weeks of treatment (Pearson r2 = 0.69; P = 0.020). 
Representative coronal 89Zr-bevacizumab PET images of a patient scanned before (A) and after (B) 3 weeks of treatment. 
The patient had a large tumor mass in the chest wall. 89Zr-bevacizumab PET could be performed in 6 of 10 patients of which 
5 underwent repeated scan procedures. The CT-scan pre-treatment is shown in panel C. Panel D shows a heterogeneous 
response in individual tumor lesions (n = 23) between baseline and follow-up, with an average increase of SUVmax of 5.7%.
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One patient with HER2 positive breast cancer experienced a confirmed PR after 8 weeks. 
An additional seven patients (3 with HER2 positive breast cancer and 4 with ER positive 
breast cancer) experienced confirmed SD (Table 2), resulting in a disease control rate of 
50% (95% confidence interval 24.7%-75.3%). Median time to progression was 3 months 
(range 1-10). Five patients experienced time to progression >6 months. A waterfall plot of 
best responses on CT showed a decrease of mean tumor size in most patients (Figure 5).
Pharmacokinetics
Supplementary Figure 1 shows mean blood concentration-time profiles for NVP-AUY922 
(A) and its metabolite BJP762 (B). Following the initial rapid decline in concentration 
levels after the infusion, NVP-AUY922 was eliminated slowly with a flat terminal phase half 
life of 120 hours (range 54-404). Area under de curve (AUC) from time zero until the last 
measurable samples were 7.7*103±2.5*103 and 4.5*103±2.0*103 for respectively AUY922 
and BJP762 in the HER2 group and 9.9*103±2.6*103 and 1.3*104±2.1*104 for respectively 
AUY922 and BJP762 in the ER group. Peak concentrations were observed at the end of 
infusion for both NVP-AUY922 and BJP762, suggesting the rapid biotransformation from 
NVP-AUY922 to BJP762 in vivo. It should be noted that whole blood AUY922 is measured, 
including the fraction encapsulated in red blood cells (which is not available for 
metabolization): this makes the apparent half-life longer for parent AUY922 as compared 
to its metabolite BJP762. These results were in line with the findings in the first in human 
phase I and ongoing phase II studies29,33.
Maximal percentage change in sum of longitudinal axis of target lesions on CT, between baseline and 8 weeks of treatment in 
patients with HER2 positive (A) and ER positive (B) breast cancer. Repeated CT was performed in 9 of 10 patients with HER2 




This study provides early evidence that the change between tumor uptake on baseline and 
early 89Zr-trastuzumab PET after 3 weeks of treatment with HSP90 inhibitor NVP-AUY922, 
had a moderate positive correlation with change in tumor size on CT after 8 weeks of 
treatment. In contrast, early FDG-PET, performed after 4 weeks of treatment, did not 
correlate with change in tumor size on the 8 week CT. 
In a preclinical model, 18F-FDG uptake was minimally affected by NVP-AUY922 
administered to a spheroid model with BT474 breast cancer cells34. Previously, 17AAG 
effect could be visualized in vivo by reduced radiolabeled trastuzumab uptake, but not by 
means of FDG-PET24. These results all support that more specific imaging of targets is more 
useful to assess the effects of HSP90 inhibition. In human tumor-bearing mice, we showed 
that HER2 and VEGF downregulation could be visualized after treatment with an HSP90 
inhibitor22,23. Now also in the clinical setting, we observed that novel PET probes such as 
89Zr-trastuzumab can potentially be used to provide whole body insights into response of 
HER2 amplified breast cancer to NVP-AUY922. Interestingly, we found a heterogeneous 
effect on the SUVmax, within tumor lesions, both within and between patients. This effect 
was in line with both heterogeneous intra- and inter patient tumor responses on CT. A 
further application of 89Zr-trastuzumab PET could be predefining areas of tumor that are 
not responding to targeted treatment with HSP90 inhibitors such as NVP-AUY922. 
Biopsying such areas would provide valuable insights in the biology of HSP90 resistance in 
the tumor. Also interlesional heterogeneity of gene expression is increasingly recognized as 
a relevant factor which is likely to affect treatment response35,36. The precise clinical 
implications of in vivo heterogeneity of HER2 expression are currently further investigated 
in the Dutch multicenter IMPACT breast trial (Trial Registration ID: NCT01832051). With 
regard to the use of 89Zr-trastuzumab- or 89Zr-bevacizumab PET it should be taken into 
account that not much is known about reproducibility of the scans in cancer patients. 
However, a test-retest set up for this type of scan requires an interval of at least two weeks 
because of the particularly long half-life of 89Zr-tracers. Such an interval would require 
otherwise stable conditions, which is not typically the case in metastatic cancer patients. As 
a result, variation in measurements can also be induced by a factor such as tumor growth. 
In addition, the often necessary start of systemic treatment in (rapidly) progressive disease, 
would induce further variability. In a preclinical study there was no significant difference 
in uptake of 89Zr-trastuzumab-F(ab’)2 in SKBR3 tumor bearing mice without treatment 
(interval between two scans 7 days)37.
We did not find a correlation between uptake change on 89Zr-bevacizumab PET and CT. 
This could be due to the fact that most lesions found on 89Zr-bevacizumab PET were bone 
lesions which were not measurable on CT. Another potentially contributing factor is that 
HIF-1α is likely a less prominent client protein of HSP90 than HER238. HSP90 can influence 
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angiogenesis in multiple ways, including degradation of HIF-1α which drives production 
of VEGF or degradation of VEGF receptor. Although angiogenesis is a hallmark of cancer39, 
inhibition of angiogenesis is less critical to response to treatment of breast cancer as 
evidenced by an increasing number of studies showing no clinical benefit of bevacizumab 
in breast cancer40,41. Moreover in breast tumors, 89Zr-bevacizumab uptake was consistently 
lower than in renal cell cancer25,27. In view of this, the fact that ER itself is influenced by 
HSP90 inhibition, and that it is now possible to visualize ER on tumor lesions by means of 
whole body 18Fluorestradiol (FES) PET, it would be of great interest to use FES-PET in 
patients with ER positive breast cancer receiving HSP90 inhibition. However, at time of 
design of this study FES was not clinically available in our clinic. So, while 89Zr-bevacizumab 
PET cannot be used to assess treatment response, a recent clinical study in breast cancer 
patients indicated that it may be of use in the setting of primary tumor detection27. In 
addition, in patients with HER2 positive metastatic breast cancer, HER2-ECD at baseline 
and decrease during treatment, positively correlated with tumor response. This is in line 
with a previous trial, in which HER2-ECD also correlated to trastuzumab and paclitaxel 
response28. Pharmacodynamic markers such as HSP70 induction and PK parameters 
confirmed pharmacokinetic and pharmacodynamic findings observed in a previous phase 
I study29. 
In the present trial, we found an encouraging clinical benefit rate of 50% in heavily pre-
treated breast cancer patients with progressive disease at start of treatment. Studies with 
first generation HSP90 inhibitors only demonstrated modest clinical benefit in HER2 
amplified breast cancer30, however in this trial the clinical benefit was also seen in ER 
positive breast cancer. NVP-AUY922 is currently further evaluated in combination with 
trastuzumab and has shown encouraging results in a phase II study17. In light of our results, 
it would also be of interest to further evaluate HSP90 inhibition for the treatment of ER 
positive metastatic breast cancer, particularly because the ER itself is a client protein of 
HSP90. 
Concluding, in this clinical trial in patients with advanced HER2 or ER positive metastatic 
breast cancer, effect of treatment with HSP90 inhibitor NVP-AUY922, on in vivo degradation 
of HER2 and VEGF was assessed with 89Zr-trastuzumab PET or 89Zr-bevacizumab PET. 89Zr-
trastuzumab PET results at 3 weeks positively correlated with CT responses in individual 
lesions. Thus novel PET probes such as 89Zr-trastuzumab might provide insights into 
responses to novel agents active in HER2 amplified breast cancer, such as NVP-AUY922. 
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 Arithmetic mean concentration-time profiles for AUY922 (A) and BJP762 (B) blood levels in hours post NVP-AUY922 infusion.
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Table 1. Most common adverse events 




Patients with at least one AE 16 (100.0)
Diarrhea 16 (100.0)
Fatigue 13 (81.3)
Night blindness 11 (68.8)
Nausea 10 (62.5)
Vision blurred 8 (50.0)
Headache 7 (43.3)
Photopsia 7 (43.8)
Decreased appetite 5 (31.3)
Vomiting 5 (31.3)
Back pain 4 (25.0)
Rash 4 (25.0)
Abdominal pain 3 (18.8)
Anemia 3 (18.8)
Dry mouth 3 (18.8)
Non-cardiac chest pain 3 (18.8)
Pain in extremity 3 (18.8)
ALAT increased 2 (12.5)
Constipation 2 (12.5)
Cough 2 (12.5)
Halo vision 2 (12.5)
Muscle spasms 2 (12.5)
Pain of skin 2 (12.5)
Photophobia 2 (12.5)
Retinogram abnormal 2 (12.5)
Urinary tract infection 2 (12.5)
Weight decrease 2 (12.5)
Table 2. Adverse events with CTCAE grades 3 and 




Patients with at least one grade 3 or 4 AE 7 (43.8)
ALAT increased 2 (12.5)
Dyspnea 1 (6.3)
Flank pain 1 (6.3)
Hyperbilirubinemia 1 (6.3)
Hypercalcemia 1 (6.3)
Malignant pleural effusion 1 (6.3)
Night blindness 1 (6.3)
Pleural effusion 1 (6.3)
Urosepticemia 1 (6.3)
Vomiting 1 (6.3)
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Table 3. 89Zr-trastuzumab uptake per lesion and per patient (SUVmax) 
before and during treatment with AUY-922.




























































Table 4. 89Zr-bevacizumab uptake per lesion and per patient (SUVmax) 
before and during treatment with AUY-922. 
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Cancer is treated with surgery, radiotherapy and/or systemic treatment including 
chemotherapy, targeted and immunotherapeutic anticancer drugs. Chemotherapeutic 
drugs have proven efficacy in several tumor types and their regimens differ in side effects. 
Therefore ongoing research is performed to find the most effective treatment with the 
fewest side effects. Targeted drugs aim at particular molecular tumor characteristics. 
Assessment of these characteristics prior to and early during treatment, can support 
treatment response prediction and treatment decisions at an early stage. This would clearly 
benefit the patient. In case of successful response prediction, patients who likely will not 
respond to a certain therapy do not have to suffer from the side-effects and can move on to 
another therapy sooner. Molecular tumor characterization is usually performed on the 
primary tumor, or on a metastasis biopsy. However, such a biopsy is not always feasible, 
and it can only provide static information disregarding possible conversion and 
heterogeneity of molecular characteristics1,2. In this setting, molecular imaging with for 
example positron emission tomography (PET) is of interest. It can be easily serially 
performed by developing a monocloncal antibody tracer against a tumor membrane 
receptor or a ligand. Examples are radiolabeled trastuzumab and bevacizumab, antibody 
directed against human epidermal growth factor receptor-2 (HER2) and vascular endothelial 
growth factor-A (VEGF-A).
This thesis aimed at improving cancer treatment and allocation, by assessing optimal 
treatment duration, detection and monitoring of treatment. Optimal chemotherapeutic 
regimen duration was evaluated in patients with gestational trophoblastic neoplasia. 
Detection of targets in tumor lesions as well as monitoring treatment response was evaluated 
in breast cancer patients by means of radio-labeled monoclonal antibody imaging of HER2 
and VEGF-A. 
Chapter 1 provides a concise background and outline of this thesis. 
In chapter 2 treatment of gestational trophoblastic neoplasia is described. Therapy of 
low risk gestational trophoblastic neoplasia not responding to monotherapy and primary 
high risk gestational trophoblastic neoplasia consists of polychemotherapy. Currently 
standard treatment consists of actinomycin D (0.5 mg days 1-2), etoposide (100 mg/m2 
days 1-2), methotrexate (300 mg/m2), folinic acid (15 mg), vincristine (0.8 mg/m2 day 8), 
cyclophosphamide (600 mg/m2 day 8) (EMA/CO). EMACP, a regimen consisting of 
etoposide (100 mg/m2 days 1-5), methotrexate (300 mg/m2 day 1), cyclophosphamide 
(600 mg/m2 day 1), actinomycin D (0.5 mg/m2 day 2) and cisplatin (50 mg/m2 day 4) has 
also proven efficacy. Etoposide (100 mg/m2 days 1-5) and cisplatin (20 mg/m2 days 1-5) 
(EP) may be an alternative regimen with comparable efficacy and a shorter treatment time. 
After normalization of the βhCG serum levels, patients treated with EMACP received 2 
additional consolidation cycles, which is not the case for EP. We evaluated the safety, 
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efficacy, and treatment time of EP. All patients with high risk gestational trophoblastic 
neoplasia who were treated since 2001 with EP at our institution were included in this 
cohort analysis and compared with the results of patients treated between 1984-2001 with 
EMACP. Thirteen patients started treatment with EP and and 16 patients with EMACP. 
With a median follow up duration of 173 months (range 11-344) overall survival rates are 
comparable for both regimens (EP 92.3%, EMACP 93.8%; P = 0.88). Median treatment 
time was shorter with EP (EP 78 days, range 63-84 days; EMACP 110 days, range 84-168 
days;  (P = 0.006). In this retrospective single institution analysis of the treatment of high 
risk gestational trophoblastic neoplasia, the EP regimen has survival rates in the same range 
as EMACP with comparable toxicity and a shorter treatment time.
In chapter 3, the role of molecular imaging in drug development is described where 
imaging of HER2 and VEGF serve as role models. Molecular imaging with radiolabeled 
monoclonal antibodies can give information about antibody tumor uptake and about 
presence of the target of the antibody in all tumor lesions across the patient’s body. PET can 
be used to evaluate changes in targets as a consequence of treatment with monoclonal 
antibody and non-monoclonal antibody targeted drugs. It can also potentially contribute 
to optimal patient selection for targeted therapy. 
Increasingly, the microenvironment of the primary tumor and its metastases is awarded 
a central role in the process of tumor progression and metastatic dissemination. Therefore, 
targeting factors in the microenvironment that support the process of tumor progression 
and metastases, can be a rational way to improve therapy of cancer patients. In chapter 4, 
we focus on the current knowledge of processes in the microenvironment involved in 
breast cancer. The number of drugs targeting key factors in these processes is expanding, 
and the available clinical data is increasing. Therefore current strategies for intervention 
and prediction of treatment response are outlined. At present, targeting the bone metastatic 
niche and obesity induced metabolic stimulation, have already shown to be clinically 
effective. Targeting the immune system is a field of great research interest in cancer 
treatment, currently showing very promising results in clinical trials. In earlier stages of 
development are compounds targeting tumor cell migration. However, targeting 
angiogenesis or matrix remodeling appears to be of limited clinical relevance in breast 
cancer treatment so far. 
In chapter 5, the focus is HER2 again. We reported earlier on indium-111 (111In)-
trastuzumab scintigraphy in 17 patients with human epidermal growth factor receptor-2 
(HER2) overexpressing metastatic breast cancer after the first loading dose of trastuzumab. 
In the present study, we present the analyses of the patients who underwent a baseline- and 
second scintigraphy procedure during trastuzumab treatment. This provided unique data 
to assess the presence of HER2 measured by 111In-trastuzumab uptake during treatment 
with trastuzumab. A loading-dose trastuzumab of 4 mg/kg, and thereafter once-a-week 
trastuzumab doses of 2 mg/kg for 11 weeks, and concomitant paclitaxel once every 3 
weeks (175 mg/m2) was administered. 111In-trastuzumab was injected on day 1 (t = 0) and 
after 11 weeks. Whole-body planar scintigraphy was acquired on 4 time points between 15 
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minutes- 7 days postinjection. Differences in tumor and organ uptake were determined 
from radiation dosimetric data and expressed as residence time (defined as area under the 
curve of radioactivity versus time). In total 25 tumor lesions in 12 patients were visualized, 
all on both scintigraphy procedures. The tumor residence time decreased by 19.6 ± 53.8% 
at t = 1 v t = 0, while 111In-trastuzumab uptake in most normal organs did not differ. 111In-
trastuzumab levels in the cardiac blood pool were higher at t = 1. Change in residence time 
was not related with tumor response as measured by conventional imaging. So, trastuzumab 
treatment did not mask visualization of HER2 positive tumor lesions by 111In-trastuzumab 
scintigraphy. 
In chapter 5B, the findings with Zirconium-89 (89Zr)-trastuzumab PET in an exceptional 
patient are described. The patient described in this chapter had a history of two different 
breast tumors; one was HER2 negative, the other HER2 positive. Two years after diagnosis, 
metastases were found on CT. The tumor lesions were difficult to reach for a biopsy. On 
89Zr-trastuzumab PET, there was uptake in the metastatic lesions, indicating the presence 
of HER2 as target for treatment. In line with the scan results, this patient was treated for 
HER2 positive metastatic breast cancer with paclitaxel and trastuzumab, with a partial 
tumor response.
The clinical feasibility of VEGF-A imaging by means of 89Zr-bevacizumab PET in 
primary breast cancer is shown in the study described in chapter 6. This study was 
performed to evaluate 89Zr-bevacizumab uptake in primary breast cancer. Prior to surgery, 
breast cancer patients underwent a PET/CT scan of breast and axillary regions, 4 days after 
37 MBq 89Zr-bevacizumab administration. 89Zr-bevacizumab uptake was quantified as the 
maximum standardized uptake value (SUVmax) and correlated with VEGF-A expression 
measured by Enzyme-linked Immuno Sorbent Assay (ELISA) of tumor tissue. In 25 of the 
26 tumor lesions we could visualize the tumor. SUVmax was higher in tumors (1.85 ± 1.22, 
range 0.52-5.64) than in normal breast (0.59 ± 0.37; range, 0.27-1.69; P < 0.001) of 
individual patients. The only non-PET detected tumor was 10 mm in diameter, which was 
presumably below the detection limit of the camera. VEGF-A levels in 17 assessable tumors 
were higher compared to normal breast tissue in all cases (VEGF-A/mg protein 184 ± 169 
pg v 10 ± 21 pg; P = 0.001), whereas 89Zr-bevacizumab uptake correlated with VEGF-A 
tumor levels (r = 0.49) measured by ELISA. Tumor specific imaging of VEGF-A is feasible 
in the vast majority of primary breast tumors.
One of the therapies for which molecular imaging could serve as an early biomarker is 
HSP90 inhibition. In preclinical models the HSP90 inhibitor NVP-AUY922 downregulates 
the expression of many oncogenic HSP90 client proteins (including HER2), and inhibits 
angiogenesis by downregulating hypoxia inducible factor 1α (HIF-1α) resulting in 
decreased VEGF-A excretion. In chapter 7, a phase 2 study with NVP-AUY922 in metastatic 
breast cancer patients is described. 70 mg/m2 NVP-AUY922 was administered intravenously 
in a weekly schedule to patients with advanced HER2 or ER positive breast cancer. 
Biomarker analysis consisted of serial PET imaging with 18F-fluordeoxyglucose (FDG), 89Zr-
trastuzumab or 89Zr-bevacizumab. Response evaluation was performed according to 
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RECIST1.0. FDG, 89Zr-trastuzumab and 89Zr-bevacizumab distribution were scored by 
calculating the maximum SUVmax. In blood samples, serial HSP70 levels, extracellular form 
of HER2 (HER2-ECD) were measured. NVP-AUY922 was administered to 16 patients (10 
patients with HER2 positive and 6 with ER positive breast cancer). One partial response 
was observed (HER2 positive tumor); seven patients showed stable disease (3 HER2 
positive, 4 ER positive tumors). SUVmax change in individual tumor lesions on baseline 
versus 3 weeks 89Zr-trastuzumab PET was heterogeneous and related to size change on CT 
after 8 weeks treatment (r2 = 0.69; P = 0.006). 89Zr-bevacizumab PET and FDG PET did not 
correlate with CT. Thus novel PET probes such as 89Zr-trastuzumab can be used to provide 
insights into responses to novel agents active in HER2 amplified breast cancer such as 
NVP-AUY922. 
SUMMARY AND FUTURE PERSPECTIVES
8
132
Discussion and future perspectives
Improving therapy for gestational trophoblastic neoplasia
In the exploratory study in chapter 2 we showed that it seems feasible to decrease the 
intensity of the treatment of high-risk gestational trophoblastic neoplasia and put 3 or 4 
cycles of EP as initial treatment. Clearly, a randomized control trial is needed to confirm the 
findings in chapter 2 prospectively. Such a trial should also encompass long-term side 
effects. 
Further establishment of HER2 and VEGF-A imaging for clinical use
In chapters 5 and 7, HER2 status of metastatic lesions could be visualized by means of 89Zr-
trastuzumab PET. In view of the proven benefit of anti-HER2 therapy in HER2 expressing 
breast cancer, when standard workup fails to establish the HER2 status of metastatic 
lesions, 89Zr-trastuzumab PET could be of potential value. Therefore, we are currently 
performing a prospective multicenter study to assess the role of 89Zr-trastuzumab PET in 
individualizing therapy (NCT 01957332). To evaluate the clinical utility of 89Zr-trastuzumab 
PET at first presentation of metastatic breast cancer a trial is ongoing (NCT 01832051).
Molecular imaging of HER2 as biomarker for response to multiple treatments
The value of 89Zr-trastuzumab PET upfront to select lesions not responding to treatment 
with trastuzumab-DM1 (T-DM1) is currently studied (NCT 0565200). T-DM1 is an anti-
HER2 antibody-drug conjugate. DM1 is a highly potent derivate of the antimicrotubule 
agent maytansine and its trastuzumab derived form combines the HER2-targeting with the 
intracellular delivery of DM13. Whether this will imply that heterogeneic metastatic disease 
needs a heterogeneic treatment, in which non-responding lesions may be more suitable for 
local treatment, will have to be examined in future studies. 
Molecular imaging as screening tool
Tumor specific imaging, making use of molecular characteristics of the tumor, might 
potentially be of value as screening tool for early breast cancer. In this setting, a technique 
without radiation burden is preferable. The current estimated radiation burden of 89Zr-
bevacizumab and 89Zr-trastuzumab PET is 19 milliSieverts (mSv) per tracer injection. To 
make optimal use of the tumor specificity of molecular imaging of VEGF-A while 
overcoming radiation issues, bevacizumab was also linked to the near-infrared fluorescent 
dye IRDye 800CW. This technique was tested in human xenograft-bearing athymic mice 
and detected tumor lesions in vivo. 800CW-bevacizumab detected lesions in the 
submillimeter range with a clinical intraoperative camera4, which is more specific than 
89Zr-bevacizumab PET and X-ray. Currently, a study with 800CW-bevacizumab in early 
breast cancer patients (NCT01508572) is almost finalized. The aim of this study is to 
determine the uptake of the VEGF-A targeting fluorescent tracer in breast cancer tissue, 
with diffuse optical tomography before and during surgery. With diffuse optical tomography, 
CHAPTER 8
133
we expect to visualize the tumor in vivo. When the tracer turns out to be tumor specific this 
may support further translation of this tracer for use during screening of breast cancer and 
other tumor types. Other antibodies such as trastuzumab can also be labeled with 800CW4. 
It is expected that major progress will be made in the clinical translation of optical imaging 
with fluorescent labeled antibodies as not only during surgery but also use during 
endoscopies is currently explored.
Molecular imaging in other tumor types
As HER2 and especially VEGF-A play also a role in other tumor types, experience with 
molecular imaging can be translated to these tumors, for example in gestational trophoblastic 
neoplasia. Placental site trophoblastic tumor exhibited strong staining for VEGF, and 
gestational choriocarcinoma showed strong staining for VEGF receptor-3. Therefore, 
detection of metastases and even treatment in these subtypes might potentially be performed 
by means of molecular imaging. Further research in this rare disease is needed.
In conclusion, this thesis describes various aspects of optimizing patient- and treatment 
selection, which may ultimately contribute to improve outcome. 
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Ondanks vele nieuwe behandelingen is kanker is nog steeds één van de belangrijkste 
doodsoorzaken in de Westerse wereld. Kanker wordt behandeld met chirurgie, radiotherapie 
en/of systemische behandeling. Als systeemtherapie worden naast chemotherapie ook, 
doelgerichte medicijnen gegeven. Sinds kort is immunotherapie in opkomst. De 
bijwerkingen van anti-kanker behandelingen hangen samen met het soort medicijn, de 
dosering van het medicijn en de duur van de behandeling. Er wordt veel onderzoek verricht 
naar wat de meest optimale behandeling is voor patiënten.
Doelgerichte medicijnen zijn gericht tegen specifieke moleculaire kenmerken van de 
tumor. Het evalueren van deze kenmerken voorafgaande en vroeg tijdens de behandeling, 
kan mogelijk de respons op behandeling voorspellen, of in een vroeg stadium de beslissing 
om een behandeling te staken of te continueren ondersteunen. De patiënt hoeft dan niet 
nodeloos bijwerkingen te ervaren en er kan eerder worden overgegaan op een andere 
behandeling. We weten dat bijvoorbeeld het bepalen van de oestrogeenreceptor (ER) en de 
humane epidermale groeifactor receptor 2 (HER2) bij borstkanker zin heeft. Moleculaire 
typering van de tumor wordt meestal uitgevoerd op de primaire tumor of op een biopt van 
een uitzaaiing. Het nemen van biopten is echter niet altijd  mogelijk, en het nadeel van een 
biopt is daarnaast dat het alleen een momentopname van de tumor biedt1,2. Het in beeld 
brengen van de moleculaire kenmerken met een radioactieve speurdosis gericht tegen een 
eigenschap met positron emissie tomografie (PET) is niet invasief, het kan een overzicht 
geven van het gehele lichaam en het kan bij herhaling worden uitgevoerd. 
Een voorbeeld van een moleculair kenmerk voor moleculaire beeldvorming is HER2. 
HER2 is een belangrijke groeifactorreceptor en fosforylatie van HER2 leidt tot tumorcelgroei 
en differentiatie. In 20-25% van de borstkankers is er sprake van overexpressie van HER2. 
Het doelgericht behandelen gericht op deze receptor met trastuzumab geeft overlevingswinst 
in de adjuvante setting en bij vrouwen met uitgezaaide borstkanker3,4. Een ander voorbeeld 
is de vasculaire groeifactor (VEGF-A), die een sleutelfactor is in de omgeving van de 
tumorcellen, het micromilieu, waar het vaatnieuwvorming veroorzaakt. VEGF-A wordt 
door vele verschillende soorten kanker tot overexpressie gebracht. Radioactief gelabelde 
monoklonale antilichamen, gericht tegen HER2 en VEGF-A,  kunnen als PET tracer deze 
eigenschappen afbeelden. 
In dit proefschrift wordt onderzoek beschreven dat gericht is op het verbeteren van de 
behandeling van kanker door het evalueren van de optimale behandelduur, de detectie van 
tumoren en het monitoren van de behandeling. Het optimale chemotherapeutisch regime 
werd geëvalueerd bij patiënten met een persisterende trofoblast. Detectie van moleculaire 
kenmerken van tumorlaesies en tumorrespons op behandeling werd geëvalueerd bij 
patiënten met borstkanker door middel van beeldvorming met radioactief gelabelde 
monoklonale antilichamen gericht tegen HER2 en VEGF-A. 
In hoofdstuk 1 wordt een korte inleiding gegeven en worden de verschillende hoofdstukken 
geïntroduceerd. In hoofdstuk 2 wordt de behandeling van een persisterende trofoblast 
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beschreven. Behandeling van laag risico persisterende trofoblast die niet reageert op monotherapie 
evenals primair hoog risico persisterende trofoblast bestaat uit polychemotherapie. De 
standaardbehandeling bevat chemokuren met actinomycine D (0,5 mg dag 1-2), etoposide (100 
mg/m2 dag 1-2), methotrexaat (300 mg/m2), folinezuur (15 mg), vincristine (0,8 mg/m2 dag 8) 
en cyclofosfamide (600 mg/m2 dag 8) (EMA / CO). EMACP, een regiem bestaande uit etoposide 
(100 mg/m2 dag 1-5), methotrexaat (300 mg/m2 dag 1), cyclofosfamide (600 mg/m2 dag 1), 
actinomycine D (0,5 mg/m2 dag 2) en cisplatine (50 mg/m2 dag 4) is ook bewezen werkzaam. 
Etoposide (100 mg/m2 dag 1-5) en cisplatine (20 mg/m2 dag 1-5) (EP) kan een alternatief zijn 
met dezelfde werkzaamheid en een kortere behandeltijd. Na normalisatie van het βhCG kregen 
patiënten behandeld met EMACP nog 2 consolidatiekuren, wat niet het geval is bij EP. In dit 
hoofdstuk evalueerden we de veiligheid, effectiviteit en behandelduur van EP en EMACP. Alle 
patiënten met een hoog risico, of een laag risico persisterende trofoblast die niet reageerde op 
monotherapie en werden behandeld sinds 2001 met EP in het Universiteits Medisch Centrum 
Groningen zijn vergeleken met de patiënten die tussen 1984-2001 werden behandeld met 
EMACP. Dertien patiënten kregen EP en 16 patiënten  EMACP. Met een mediane follow-up duur 
van 173 maanden (range 11-344) was de overleving vergelijkbaar voor beide regimes (EP 
92,3%, 93,8% EMACP, P = 0,88). De mediane behandelingsduur was korter met EP (EP 78 
dagen, range 63-84 dagen; EMACP 110 dagen, range 84-168 dagen; (P = 0,006)). Concluderend 
kan gesteld worden dat in deze retrospectieve  analyse EP dezelfde overleving had als EMACP 
met vergelijkbare toxiciteit en een kortere behandelduur. 
In hoofdstuk 3 wordt de rol van moleculaire beeldvorming in de ontwikkeling van 
doelgerichte anti-kankertherapie beschreven met de beeldvorming van HER2 en VEGF als 
voorbeelden. Moleculaire beeldvorming met radioactief gelabelde monoklonale 
antilichamen kan informatie geven over de aanwezigheid van de doelwitten voor deze 
doelgerichte behandelingen, bij alle tumorlaesies van de patiënt. PET kan gebruikt worden 
om veranderingen van de eigenschappen van de tumor door behandeling met een 
radioactief antilichaam te evalueren. Deze techniek kan mogelijk ook bijdragen om 
patiënten optimaal te selecteren voor doelgerichte anti-kanker therapie. 
Steeds vaker wordt het micromilieu van de tumor, namelijk de directe omgeving waarin 
de tumorcellen zitten, een belangrijke rol toegedicht in het proces van tumorgroei en 
uitzaaiing. Factoren die deze processen ondersteunen zouden een doelwit kunnen zijn voor 
behandeling. In hoofdstuk 4 wordt een uitgebreide literatuurbeschrijving gegeven van deze 
doelwitten in het micromilieu, die mogelijk gebruikt kunnen worden om zo kanker te 
behandelen. Ook worden de beschikbare methodes beschreven die het effect van behandeling 
kunnen monitoren en voorspellen. Een behandeling gericht op bot, met bisfosfonaten, kan 
een gunstig effect hebben op zowel de borstkanker zelf als eventuele uitzaaiingen in bot. 
Overgewicht beïnvloedt de energiehuishouding van (borst)kanker op een ongunstige 
manier, en tegengaan van overgewicht wordt een steeds belangrijker aspect bij behandeling 
van kanker. Naar het beïnvloeden van het immuunsysteem, om uitzaaiingen op te ruimen, 
wordt op dit moment veel onderzoek gedaan. Het beïnvloeden van de bloedvatvoorziening 




In hoofdstuk 5 wordt een studie beschreven waarin onderzocht wordt wat het effect van 
trastuzumab-behandeling is op de opname van 111In-trastuzumab. Een eerder artikel 
beschreef 111In-trastuzumab scintigrafie in 17 patiënten met een HER2 positief uitgezaaide 
borstkanker5. Om het effect van trastuzumab-behandeling op orgaanaccumulatie, 
radiatiedosimetrie en tumoropname van 111In-trastuzumab te evalueren, presenteren we 
hier aanvullende analyses van dezelfde patiënten die zowel voorafgaand aan, als tijdens 
behandeling met trastuzumab, een scintigrafie-procedure ondergingen. Patiënten kregen 
zes kuren van 3 weken met trastuzumab (2 mg/kg wekelijks na een oplaaddosis van 4 mg/
kg) en paclitaxel (175 mg/m2 3-wekelijks) toegediend. 111In-trastuzumab werd geïnjecteerd 
op dag één van cyclus één (t = 0) en dag 15 van cyclus vier (t = 1). Whole-body scintigrafie 
werd verricht op vier momenten tussen 15 minuten en 7 dagen na de injectie met 111In-
trastuzumab. Het verschil in tumor- en orgaanopname werd bepaald door middel van 
radiatiedosimetrie en uitgedrukt in residentietijden (gedefinieerd als oppervlakte onder de 
curve van radioactiviteit versus tijd). Bij 12 van de 17 patiënten konden beide scintigrafie-
procedures genalyseerd worden. In totaal werden er 25 tumorlaesies gevisualiseerd, allen 
aantoonbaar bij beide scintigrafie-procedures. De residentietijden van de opname van de 
tracer in normale organen bleven gelijk tussen t = 0 en t = 1, met uitzondering van een 
toename in het bloedcompartiment (P = 0,014). De residentietijden van de opname van de 
tracer in de tumoren verminderde met 19,6% ± 53,8% (P = 0,03). Verandering van de 
residentietijd was niet gerelateerd aan tumorrespons zoals gemeten met conventionele 
beeldvorming. Ondanks behandeling met trastuzumab was het dus nog steeds goed 
mogelijk HER2 positieve tumoren af te beelden. 
In hoofdstuk 5B worden de bevindingen met 89Zr-trastuzumab PET bij een bijzondere 
patiënt beschreven. Deze patiënte werd 2 jaar eerder gediagnosticeerd met twee primaire 
borstkankers waarvan er één wel en de andere niet  HER2 tot overexpressie bracht. Op CT 
bleek zij meerdere uitzaaiingen te hebben, die allen moeilijk bereikbaar waren voor een 
biopt. Op 89Zr-trastuzumab PET werd er traceropname gezien in meerdere uitzaaiingen. De 
patiënt werd behandeld voor een HER2 positief uitgezaaide borstkanker met paclitaxel en 
trastuzumab waar de uitzaaiingen goed op reageerden.
De klinische haalbaarheid van 89Zr-bevacizumab PET bij primaire borstkanker wordt 
beschreven in hoofdstuk 6. Deze studie werd uitgevoerd om 89Zr-bevacizumab opname in 
borstkankers te evalueren. Bij patiënten met primaire borstkanker werd een 89Zr-
bevacizumab PET scan van de borsten en de oksels verricht voorafgaand aan de operatie. 
89Zr-bevacizumab opname werd gekwantificeerd als de maximum standaard uptake value 
(SUVmax) en gecorreleerd met de VEGF-A expressie van de tumor gemeten met Enzyme-
Linked Immuno Sorbent Assay (ELISA). Op de PET scan werden 25 van de 26 tumoren 
gevisualiseerd. De SUVmax was hoger in tumoren (1,85 ± 1,22, range 0,52-5,64) dan in het 
normale borstweefsel (0,59 ± 0,37; range, 0,27-1,69; P < 0,001). De enige niet gedetecteerde 
tumor was relatief klein ( diameter 10 mm). VEGF-A levels van 17 analyseerbare tumoren 
waren in alle gevallen hoger dan in  het normale borstweefsel van dezelfde patiënte, en 
89Zr-bevacizumab uptake correleerde met VEGF-A tumorspiegels (r = 0,49). Tumor 
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specifieke beeldvorming van VEGF-A maakt het mogelijk het grootste deel van de primaire 
borstkankers af te beelden.
Eén van de therapieën waarbij moleculaire beeldvorming als vroege voorspeller zou 
kunnen dienen is bij het gebruik van een  remmer van Heat Shock Protein-90 (HSP90). De 
HSP90 remmer NVP-AUY922 verlaagt de expressie van vele oncogene eiwitten die van 
HSP90 afhankelijk zijn (inclusief HER2), en blokkeert vaatnieuwvorming indirect door het 
verlagen van hypoxia inducible factor 1α (HIF-1α) waardoor VEGF-A excretie afneemt. In 
hoofdstuk 7 wordt een fase 2 studie met de HSP90 remmer NVP-AUY922 bij patiënten 
met uitgezaaide borstkanker beschreven. NVP-AUY922, 70 mg/m2 werd eenmaal per week 
intraveneus toegediend aan patiënten met uitgebreide ER of HER2-positieve borstkanker. 
Analyse bestond uit 18F-fluordeoxyglucose (FDG), 89Zr-trastuzumab of 89Zr-bevacizumab 
PET scans, verricht voor behandeling en na respectievelijk 4 en 8 weken (FDG) en 3 weken 
(89Zr-trastuzumab of 89Zr-bevacizumab). Responsevaluatie gebeurde volgens RECIST 1.0. 
De FDG, 89Zr-trastuzumab en 89Zr-bevacizumab verdeling werd gekwantificeerd door het 
berekenen van de SUVmax. In bloed werden seriële HSP70 monsters en de extracellulaire 
vorm van HER2 (HER2-ECD) gemeten. In totaal werden 16 patiënten behandeld met NVP-
AUY922 (10 met HER2 en 6 met ER positieve borstkanker. Er was één patiënt met een 
partiële tumorrespons (HER2 positief); zeven patiënten hadden stabiele ziekte (3 HER2 
positief, 4 ER positief). Verandering van de SUVmax van individuele laesies op 
89Zr-
trastuzumab PET na 3 weken was heterogeen en gerelateerd aan de respons op de CT scan 
na 8 weken (r2 = 0,69; P = 0,006). 89Zr-bevacizumab PET en FDG PET opname verandering 
correleerde niet met de tumorrespons op de CT scan. Nieuwe PET tracers zoals 89Zr-
trastuzumab kunnen dus inzicht geven in de respons op nieuwe medicijnen zoals HSP90 
remmers bij HER2 positieve borstkanker. 
Samenvattend kan worden gesteld dat het optimaliseren van kankertherapie door het 
aanpassen van chemotherapiebehandelingen mogelijk is, en dat het gebruik van moleculaire 
beeldvorming met radioactief gelabelde antilichamen een rol kan gaan spelen bij de 
ontwikkeling van nieuwe doelgerichte anti-kanker behandelingen. Het onderzoek met 
radioactief gelabelde antilichamen dat beschreven is in dit proefschrift laat zien dat de 
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